Skip to main content

Insights of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) pandemic: a current review


COVID-19, a pandemic of the 21st century caused by novel coronavirus SARS-CoV-2 was originated from China and shallowed world economy and human resource. The medical cures via herbal treatments, antiviral drugs, and vaccines still in progress, and studying rigorously. SARS-CoV-2 is more virulent than its ancestors due to evolution in the spike protein(s), mediates viral attachment to the host’s membranes. The SARS-CoV-2 receptor-binding spike domain associates itself with human angiotensin-converting enzyme 2 (ACE-2) receptors. It causes respiratory ailments with irregularities in the hepatic, nervous, and gastrointestinal systems, as reported in humans suffering from COVID-19 and reviewed in the present article. There are several approaches, have been put forward by many countries under the world health organization (WHO) recommendations and some trial drugs were introduced for possible treatment of COVID-19, such as Lopinavir or Ritonavir, Arbidol, Chloroquine (CQ), Hydroxychloroquine (HCQ) and most important Remdesivir including other like Tocilizumab, Oritavancin, Chlorpromazine, Azithromycin, Baricitinib, etc. RT-PCR is the only and early detection test available besides the rapid test kit (serodiagnosis) used by a few countries due to unreasonable causes. Development of vaccine by several leader of pharmaceutical groups still under trial or waiting for approval for mass inoculation. Management strategies have been evolved by the recommendations of WHO, specifically important to control COVID-19 situations, in the pandemic era. This review will provide a comprehensive collection of studies to support future research and enhancement in our wisdom to combat COVID-19 pandemic and to serve humanity.


  • State-of-status on a pandemic of COVID-19

  • Discussing the controversies of origin of SARS-CoV-2

  • Overall account to understand SARS-CoV-2 at the molecular level

  • Accounting pathogenic attacks of the virus in human cells

  • Citing development of vaccines, possible drug and target sites for the treatment


The emergence of pandemics brings dares to control their harmful impacts on human health worldwide. In this catastrophic situation ofa novel infectious disease caused by a novel SARS-CoV-2,there is a flood of research papers on various aspects and impacts. The theories of virus origin have shifted the quantum towards controversies. Initially, it was recognized as a beta coronavirus and identified as able to cause a pandemic. Covering 75–80% similarity in genetic sequence to SARS-CoV, this virus embarked itself on a novel lineage with new and evolved or recombined spike proteins. However, the attention of a microbiologist or virologist is to summarize its pathogenesis and cure avenues. It is crucial to understand the mechanism of the viral evasion, pathogenesis, and apply our wisdom to find novel drugs or repurposing the existing ones.

Through back in the memories of virology, the first human coronavirus was isolated from the human’s nasal cavity by Tyrrell and Bynoe [182], as a common virus not having pathogenic features. However, all the variants of coronavirus species present in humans have originated from bats [103]. Li et al. [109] proposed a hypothesis of ancestral recombination among different coronaviruses infecting bats and pangolinsas an indicationof SARS-CoV-2 evolution and infection in humans via food chain including other modes, like air-borne transmission, and still under study. The respiratory droplets served in transmission, produced from cough and sneeze of an infected individual, and if inhaled can settle in the lungs, nasal mucosa to cause respiratory illness. Raj et al. [140, 141] has been pointed out an epidemic spread with a very high reproduction rate (R0 4.71) in the initial, but later observed to declined to 2.08, suggests a gradual decline in infection with time. The World Health Organization (WHO) has named this disease as‘COVID-19’ and classified into mild, moderate, severe, and critical categories [193]. Like other viral infections, a typical pattern of IgM and IgG production was observed by antibody profiling. The antigen presentation can also be affected by this novel coronavirus. Therefore, destroying the immune evasion of SARS-CoV-2 is imperative to find a therapeutic approach and specific drug development. There is no approved drug therapy for SARS, MERS, or even for COVID-19 infection in the current scenario, also lack clinical trial data on COVID-19 treatment makes the condition even worse. Various herbal treatments such as papain-like protease (PLpro), 3C-like protease (3CLpro) and alternative therapeutic drugs such as Lopinaviror, Ritonavir (HIV infections), Arbidol (influenza infection), Remdesivir (Ebola virus), Chloroquine and Hydroxychloroquine (Malaria), Tocilizumab (CRS secondary to CAR [chimeric antigen receptor] T-cell therapy), Teicoplanin (MERS-CoV), Glucocorticoids (pneumonia such as SARS and MERS), Baricitinib (Rheumatoid Arthritis) are in the active research trialsfor the treatment of COVID-19. Clinical data rigorously evaluated or refuted in high-quality randomized trials, particularly given that for COVID-19 has no proven safe and effective treatments yet, beside remdesivir accepted by many countries of Asia and including most severely affected Unites States of America [62]. In recent use of cc-miRNAs is advantageous to suppress infections can be an approach to control the virus in host cells during its replication [142]. Raj et al. [140, 141] reviewed notably on the mechanism (s) of virus replication, mode of infection in humans, and development of novel vaccines or drugs for the eradication and prevention.

This review figures out the status of knowledge on COVID-19 and SARS-CoV-2. In the flood of research papers, it combines all advancement in the box full of concise information. The review presents the origin of the virus, its background, pathogenicity, clinical manifestations, possible ways of treatment, and management to date. This review will be beneficial to undergraduates to the research community to have a glance of present knowledge. This further advances our understanding of SARS-CoV-2 and its impact on the present research scenario.

Origin of SARS-CoV-2 and epidemiology

The two scenarios for the origin of SARS-CoV-2 were proposed by Andersen et al. [2] that it may be borne by (i) natural selection in an animal host before zoonotic transfer; and (ii) natural selection in humans following a zoonotic transfer. As Zhu et al. [227] have published, the first pneumonic syndrome was originated from a market where sea-food and wet animals were traded. The first report of novel pneumonia (COVID-19) was in Wuhan city of Hubei province in China, occurred in late December 2019, although, the reflective analyses have identified patients with symptoms of onset short-breathing as on early December 1, 2020 [225]. Later, Tang et al. [176] suggested that SARS-CoV-2 is a new variant of coronavirus probably due to the mutation rathera recombination. Studies classify it into S and L type based on virulence and proved them originated as a result of natural selection due to the change in functional sites in the receptor-binding domain (RBD) of the SARS-CoV-2 spike and SARS-CoVs viruses from pangolin. Andersen et al. [2] explained that SARS-CoV-2 is not a purposefully manipulated virus based on molecular sequencing data and scientific shreds of evidence were credited to provide a conclusion that it is impossible to prove or disprove the other theories in the current context. There is the plausibility of balance towards the evidence of origin by one hypothesis over the other based on ongoing studies of pneumonia in humans and other animals. An article changed the quantum by adding pieces of evidence into the direction of recombination from the natural selection as suggesting strong purifying selection around the receptor-binding motif (RBM) in the spike gene and other genes among bat, pangolin and human coronaviruses, indicating similar strong evolutionary constraints in different host species [109]. Li et al. [109] gave a hypothesis that this, and/or other ancestral recombination events between viruses infecting bats and pangolins, may have a key role in the evolution of the strain that leads to the introduction of SARS-CoV-2 into humans. The proximity of animals of different species in a wet market setting increased the potential of cross-species spillover infections, by enabling recombination between more distant coronaviruses and the emergence of recombinants with novel phenotypes. As per the epidemiological timeline by WHO (!) on Jan 9, 2020, reports says Chinese authorities have determined that the outbreak is caused by a novel coronavirus. Following on Jan 24, 2020, they held an informal consultation on the prioritization of candidate therapeutic agents for use in novel coronavirus infection. On Feb 11, 2020, they announced that the disease caused by the novel coronavirus would be named COVID-19. Following best practices, the name of the disease was chosen to avoid inaccuracy and stigma and therefore did not refer to a geographical location, an animal, an individual, or a group of people. In the present state, over 69,143,017confirmed COVID-19 cases and 1,576,516 deaths were reported to WHO for the week ending 11 December 2020 [198]. The highest number of cases was alone observed in America and India, where 230,852 newly cases were reported in a 24 h (as on 12 December 2020), in America and toll of new cases is nearly similar in India i.e., 29,398 cases.

Background of SARS-CoV-2

The coronavirus is an enveloped, (+)ssRNA viruses, important to both medical and veterinary sciences. Coronavirus is distributed among mammals and birds and known that it causes respiratory, enteric, and neurologic diseases [97]. However, all the variants of coronaviruses species present in humans have been originated from the bats [10, 20]. They are membersof order Nidovirales, family Coronaviridae [43], subfamily Orthocoronavirinae, genus Betacoronavirus, and subgenus Sarbecovirus [227]. There are four genera α, β, γ, and δ represents coronaviruses. Where α and β are pathogenic to mammals and γ and δ can cause serious illnesses in birds. As mentioned earlier, coronavirus has been placed in order nidovirales, the meaning of Nido in Latin “Nest” thus its order name itself explains- these viruses nested in 3 special features. First,expression of enzyme, replicase polyprotein via ribosomal frameshifting. Second,unique enzymatic activities among the replicase protein products, and last a virion membrane envelope with multi-spanning integral membrane protein [43].

Different six strains of coronavirus within the α and β groups [131, 175] are pathogenic to humans. These six coronaviruses are named as coronavirus-229E (HCoV-229E), HCoV-OC43, HCoV-HKU1, Severe Acute Respiratory Syndrome - coronavirus (SARS-CoV), HCoV-NL63 and Middle East respiratory virus Coronavirus (MERS-CoV) [215]. These viruses are already known for their association with both the upper and lower respiratory tract and causing related diseasesin humans. Among these six human-related coronaviruses, SARS-CoV, and MERS CoV are important viruses causing serious respiratory illnesses;besides, four others cause mild diseases [228]. The present outbreak of SARS-CoV-2 is a third major spillover animal-related coronavirus to humans in the last two decades which causes a major pandemic.

Genome organizationand molecular evolution

Coronaviruses are enveloped viruses with a positive-sense single-stranded RNA genome (26–32 kb) which is largest among all RNA viruses and gives flexibility in harboring and rearrangement of their genes [172]. The genomic analysis of SARS-CoV-2 showed 75–80% similarity with SARS-COV [135, 227] and revealed the presence of coding sequence for structuralas well as non-structural proteins. These incorporate spike glycoproteins, responsible for attachment in the host cell, RNA dependent RNA polymerase (RdRp), and papain-like proteases (PLpro) [144]. The attack is also activated by priming response by host’s serine protease (TMPRSS211) [155]. When the virus invades a hostcell, it releasesits single-stranded RNA into the host cell and multiply with the assistance of host cell protein-synthesizing hormone and produces enormous amounts of the viral genome. Till now, bat presumed as the prominent host of SARS-CoV-2and an unidentified intermediate host may also be involved [135]. The tomographic study of intracellular structures involved in virus replication and assembly showed that Coronavirus is assembled completely at the pre-Golgi compartment membrane [90]. SARS-CoV-2genome possesses 14 ORF(s) which encodes 27 protein. Orf1ab is identified as the largest gene [204]. First ORF (ORF1a/b) encodes a two-thirds viral RNA, which later translated into two polyproteins of replicas, pp1a and pp1ab include 16 nonstructural proteins (nsps) as a viral replicase transcriptase complex. A very few of coronaviruses encode a hemagglutinin esterase (HE). Several other accessory proteins seem to be important for pathogenesis, but all are not characterized for their functionalities. A pre-published scientific contribution of Gordon et al. [5961] highlighted SARS-CoV-2 proteins and human proteins for host-viral interaction with a range of functions including DNA replication (Nsp1), epigenetic and gene expression regulators (Nsp5, Nsp8, Nsp13, E), vesicle trafficking (Nsp6, Nsp7, Nsp10, Nsp13, Nsp15, Orf3a, E, M, Orf8), lipid modification (Spike), RNA processing and regulation (Nsp8, N), ubiquitin ligases (Orf10), signaling (Nsp8, Nsp13, N, Orf9b), nuclear transport machinery (Nsp9, Nsp15, Orf6), cytoskeleton (Nsp1, Nsp13), mitochondria (Nsp4, Nsp8, Orf9c), and extracellular matrix (Nsp9). These nsps reorganize host’s rough endoplasmic reticulum (RER) membranes for its origination in a double-membrane vesicle envelope [90]. Research of Khailany et al. [88] stated differentiation of single point transformations from nonsynonymous substitutions in nsps 4, 5 10 12 14 and 16 as the cause of ORF1b nsp 12 14 and 16 proteins (cistrons) and distortion of ORF1a proteins nsps 4, 5, and 10 coding sequence of ORF1ab.The 5′ terminus contains the Orf1ab and 3′ terminus encode structural gene for four structural proteins S, E, M, N, and 6 accessory proteins (Fig. 1). The additional proteins are encoded by ORF3a, ORF6, ORF7a, ORF7b, and ORF8 genes [88]. SARS and SARS-CoV-2are quite similar based on amino acid level except at certain points [115] such as ORF8 a protein (present in SARS-CoV but absent in SARS-CoV-2) while, ORF8b protein of SARS-CoV-2is larger than SARS-CoV. Similarly, protein 3b is quite shorter in SARS-CoV-2 than that ofSARS-CoV [205].

Fig. 1

a The crystal structure of SARS-CoV-2 spike protein. The human ACE-2 receptor binding domain of spike protein is shown in red color (PDB ID: 6VSB) (b) 3D structure of SARS-CoV-2 main protease. Residues in the active site (His-41, Gly-143, Phe-140, and Glu-166) are shown in red color (PDB ID: 6 LU7) obtained from protein data bank (

In our study, COVID-19 (309 residues are built by the aid of the automated homology modeling, Swiss Model, web server using the crystal structure) possesses protease in complex with inhibitor n3 (PDB ID: 6 LU7, chain A) as a homolog. The model has a very high (98.00%) sequence identity to the template. Refinement was carried out in PHENIX 1.17.1_3660. The Ramachandran plot shows 100% of the residues in the allowed regions, 97.00% in the most favored region (Fig. 2) suggesting molecular identity of SARS-CoV-2 with its ancestors.

Fig. 2

Complete genomic structure of the novel SARS-CoV-2 virus (29,903 nucleotides) (Credit: [88])

Structural proteins and accessory proteins

SARS-CoV-2 encodes more than one dozen proteins, some of which are essential for viral entry and replication, and most significant are papain-like protease (PLpro), 3C-like protease (3CLpro) and spike protein. Coronavirus PLpro processes the viral polypeptide onto functional proteins and is also a deubiquitinating enzyme that dampens the host anti-viral response by hijacking the ubiquitin (Ub) system. It has been reported that SARS PLpro cleaves ISG15 (a two-domain Ub-like protein) and Lys48-linked polyUb chains and releases diUbLys48 products [11, 81]. SARS-3CLpro is a cysteine protease indispensable to the viral life cycle [122]. Coronavirus spike protein uses angiotensin-converting enzyme 2 as a receptor to help the virus enter cells. Coronaviruses contain 3 envelope protein i.e., spike (S) protein, membrane (M) protein, envelope (E) protein, and nucleocapsid (N) protein. Spike proteins are the glycoproteins [8, 18] which mediate host cell and virus binding followed by induction of human immune system, harvesting byscientists for vaccine development [137]. Wrapp et al. [203] determined the first Cryo-EM structure of novel coronavirus spike (S) protein. The S protein accommodates furin-cleavage sites between S1 and S2 processing during the biogenesis and differs from SARS-CoV and other related coronaviruses [188]. Depending on the species, coronaviruses having separate domains of the S1 subunit recognizes different receptors for host-cell entry [77]. The S1 is the most divergent and mutable region whileS2 is conserved [54, 132]. The S1 subunit is the N-terminal space that binds with the host’s membrane receptors through its receptor-binding domain (RBD) and the S2 is the C-terminal space [48, 219]. The RBD of the S1 subunit is thus, liable for the zoonotic transmission, identification of host cell, and attack (Fig. 3). In some coronaviruses, small projections also observed between the spikes are short in length, called hemagglutinin-esterase (HE) protein [66].

Fig. 3

Ramachandran plot for COVID- 19 using the crystal structure of COVID-19 main protease in complex w inhibitor n3 (PDB ID: 6 LU7, chain A) ( [32]

The M protein is an abundant glycoprotein in the coronavirus responsible for the shape of the virus [124], and important for viral assembly in the host’s cell in the lytic phase [1]. Also, M protein is an outspanning protein, theamino-terminal domainsare in the endoplasmic reticulum [113]. The 25 amino acids peptide of M protein is highlyconserved while ectodomain is least [35]. Besides,M protein interacts with ribonucleotide protein (RNP) and S glycoproteins onbudding sitesto facilitate viral particle assembly; as earlier saidby Escors et al. [45, 46] and de Haan et al. [33]. The M and N protein having a role in genome packagingwere found crucial identification at molecular level. M protein provides the signal for the genome packaging with the interaction of RNA [123] while N proteins bind to the genome and form the nucleocapsid of coronavirus [34] and support to the viral replication [118]. It frames a network of M-N interaction compelling to exclude host membranesprotein [1, 35]. N protein ranged from 43 to 50 kDa and a major component of the helical nucleocapsid of the coronavirus [99, 167]. N protein is primarily involved in the nucleocapsid formation, replication cycle of the virus, and interferes with the host cellular response against the virus [118]. The presence of the N protein at the endoplasmic reticulum (ER)-Golgi region during viral infection proved its function in the assembly and budding of the virus [149, 158, 180].

The E protein is small (8.4–12 kDa) and recondite proteins of virions, which are extremely divergent among different groups of coronaviruses (E protein express abundantly during the replication of the virus in host though their presence in the virion envelope is minor compared to others [186]. These proteins are mainly found in the ER-Golgi intermediate compartment where they mediate the assembly, budding and intracellular trafficking of infectious virions [110, 126, 218].

Pathogenicity and pathogenesis

Due to highly evolved and novelpathophysiology and virulence mechanisms, coronavirusesbecome a major cause of emerging respiratory disease outbreak, COVID-19. Coronavirus can directly enter at the cell surface after binding to the receptor or after internalization via endocytosis in the endosomal compartment [73]. The viral particles assemble in the Golgi, accumulate in dilated vesicles then transported and secreted to the cell surface, where they are released by exocytosis [108].

First and foremost, spike (S) proteins help in the attachment of coronavirus with the specific receptor play a significantrole in host cell invasion [83]. However, attachment influences with conformational changes in the virus spike protein. These conformational changes arise due to receptor binding and other activities that trigger receptors binding such as pH acidification or proteolytic activation. But novel coronaviruses modified their spike proteins with time which may be the cause of the diversity of triggers for the entry and fusion of the virus with host membrane [9, 108].

The receptor-binding domain of the S protein strengthens the affinity of S protein with its receptor which enhances the pathogenicity of SARS-CoV-2, which is like SARS-CoV [189]. SARS-CoV can fuse directly at the cell surface in the presence of relevant exogenous protease. It is believed that this route of entry is 100 to 1000-fold more efficient than the endosomal pathway [117].

The pathogenesis of SARS-CoV-2 is still mysterious and poorly understood. Scientific pieces of evidence based on genomic analysis suggested SARS-CoV-2 uses the angiotensin-converting enzyme 2 (ACE2) human receptor-like SARS-CoV [205]. A unique two-step furin activation in MERS-CoV for membrane fusion suggests strong shreds of evidence of similar mechanisms, adopted by SARS-CoV-2 [121]. The endocytosis entry of SARS-CoV has been reported either a clathrin-dependent and -independent mechanism [91]. The virus, after entry in the host’s cell releases its genome for the translation of two polyproteins and structural proteins [136, 165]. Then, viral particles matureinto the endoplasmic reticulum-Golgi intermediate compartment (ERGIC). Finally, the virus particles in the vesicles, fuse with the plasma membrane released out with envelopes and spikes [38].

The target cells of infection, its antigen is presented to the antigen presentation cells (APC) and recognized by virus-specific cytotoxic T lymphocytes (CTLs) via a presentation by major histocompatibility complex (MHC). Unfortunately, the understanding of the antigen presentation of SARS-CoV-2 is still in infancy. In the case of SARS-CoV, antigen presentation depends on MHC I and MHC II contribute in the presentation as complimentary [192]. However, during MERS-CoV infections, the MHC II molecules were found associated with the susceptibility to MERS-CoV infections [68]. Like other viral infections, a typical pattern of IgM and IgG production is evidenced by antibody profiling. The IgG antibody remains for a long time irrespective of IgM antibodies, which disappear at early phases and indicates a protective role of IgG antibody [105]. The SARS-specific IgG antibodies are primarily produced against S-protein and N-protein. The recent study illustrated the majority of CD4+ and CD8+ T cells circulating in the peripheral blood of COVID-19 patients reduces significantly, besides its excessive activation evidenced a high ratio of CD4 (3.47%) and CD38 (39.4%) cells [209]. These findings may provide valuable information for the understanding of immunological responses and rational to design vaccines against SARS-CoV-2. The antigen presentation can also be affected by this novel coronavirus. Therefore, destroying the immune evasion of SARS-CoV-2 is imperative in its treatment and specific drug development.

Clinical features

Coronaviruses cause diseases of the respiratory, hepatic, nervous system, and gastrointestinal systems in humans. COVID-19 case reports showed a patient at 5 days of fever presented with a cough, coarse breathing sounds of both lungs, and a body temperature of 39 °C. SARS-CoV-2 shows the wide spectrum of clinical features that range from asymptomatic, symptomatic to multi-organ failure [25]. Based on the severity, the disease may be classified into mild, moderate, severe, and critical [195]. Mild symptoms include dry cough, mild fever, nasal congestion, sore throat, headache, and muscle pain, moderate disease includes shortness of breath, and tachypnea while severe disease shows the respiratory distress, respiratory failure, cardiac injury, septic shock, or multiple organ failure [28, 75, 76].

Laboratory features of patients infected with COVID-19 showed leukocytosis with abnormal respiratory findings and increased levels of plasma pro-inflammatory cytokines [102]. Patient with COVID-19 infection showed the high level of cytokines and some chemokines such as IL1-β, IL1RA, IL7, IL8, IL9, IL10, basic FGF2, GCSF, GMCSF, IFNγ, IP10, MCP1, MIP1α, MIP1β, PDGFB, TNFα, and VEGFA. In severe cases of COVID-19 infection high level of pro-inflammatory cytokines was also observed including IL2, IL7, IL10, GCSF, IP10, MCP1, MIP1α, and TNFα which tend to the severity of disease [75, 76].


As discussed above,based on various scientific study COVID-19 infection shares symptoms like normal flu, influenza infection, and other pneumonia type features which makes it difficult to diagnose with accuracy and sensitivity. Thus, WHO recommended molecular (e.g. PCR) testing of respiratory tract samples for the identification and laboratory confirmation of COVID-19 cases. Reverse transcription-polymerase chain reaction (RT-PCR) based molecular tests specifically detect viral RNA. RT-PCR is the only and early detection method available for SARS-COV-2 [86].

For the most sensitive detection of COVID-19, the collection and testing of both upper and lower respiratory samples include sputum and bronchoalveolar lavage fluid (BAL) is recommended while The US centers for disease control and prevention (CDC) recommends collecting only upper respiratory swab i.e. nasopharyngeal on priority as compared to the lower respiratory tract [19]. Before the testing procedure, specimen collection and processing are also considered a part of the diagnosis from the safety point of view. In RT-PCR based diagnosis, nucleic acid extraction is primarily required and specimens related to the COVID-19 infection must be processedin Biosafety level-2 (BSL-2) cabinet and transferred to the lysis buffer containing guanidinium based inactivating agents and non-denaturing detergent and then RNA extraction should be performed [64, 93].

As per the WHO, CDC and other research committees, RT-PCR diagnosis method of COVID-19 nucleic acid detection of nasopharyngeal (NP) and oropharyngeal (OP) swab sampling and further confirmation by next-generation sequencing is the best way to diagnose the COVID-19 infection [101]. The virus remains detectable in respiratory secretions for more than 1 month in some patients, but after 3 weeks cannot be recovered for culture due to entering a dormant phase. In the initial phase during the first week of post-infection, the virus may be detected in nasopharyngeal aspirates, throat swabs, and sputum samples, while in later phases viral RNA may be more easily detected in stool samples [169]. Besides, above expensive and poorly available and affordable in many developing countries for patients. The other methods of diagnosis like X-Rays, CT-Scan, and C-Reactive Protein (CRP) test has been adopted. In the regime of emergence of COVID-19 several recommendations of using these diagnoses with adequate supporting data has been appeared (Anonymous reviewer).

Myriad scientific research suggests that the presence of a virus depends on the days of the infection and varied slightly from person to person. Thus, the standard incubation time for the COVID-19 infected patient is 14–28 days. The incubation period of coronavirus disease (COVID-19) from public confirmed cases estimated by Lauer et al. [100]. Immunoassay has been developed for the rapid detection of COVID-19 infection such as antigen-based rapid diagnostic test and host antibodies detection test but WHO does not recommend these test over RT-PCR based diagnostic test due to lack of sufficient supportive data for these immunoassay test [200].

Therapy and treatment: drugs and repurposing

There is no approved vaccines or therapies still exist for the disease. Worldwide, many of the companies working continuously for the development of vaccines or their kinds of drugs to fight with the COVID-19 infection. Development of vaccines for the COVID-19 is a quiet demanding course which is not a walk in the park.

Though S protein is currently considered to be one of the most promising targets for coronavirus vaccine development [223] and being considered for the development of vaccines to protect against MERS [4]. Supportive care is the only way to treat patients [154]. Further understanding of the structure and function of COVID-19 virus will provides elaborative knowledge on invasion and pathogenesis, to support the discovery of antiviral therapies and precise vaccine development.

Upon pathogen infection of the respiratory tract, the host immune system is activated to resist and clear the infection. Airway epithelium cells and alveolar macrophages release multiple pro-inflammatory cytokines and chemokines, such as tumor necrosis factor (TNF-α), interleukin-6 (IL-6), interferon (IFN) and other chemokines, including IL-8, monocyte chemoattractant protein-1 (MCP-1), and macrophage inflammatory protein (MIP). This release results in the attraction and activation of additional inflammatory cells, including macrophages and neutrophils, into the lungs, initiating the innate immune system that is crucial for the clearance and resolution of viral particles [82, 154]. Factors implicated in severe influenza include robust cytokine production, otherwise known as the “Cytokine storm”. Under physiological conditions, anti-inflammatory cytokines regulate the response of inflammation and attainment of equilibrium. However, the double-sided functions of cytokines could either be beneficial or detrimental to hosts. Under pathological conditions in which the balance is disrupted, pro-inflammatory responses may spiral out of control and excessive pro-inflammatory cytokines and inflammatory immune cells may contribute to additional tissue damage and inflammation [36, 130]. Also, Kumar et al. [92] carried out in silico identification of various drugs approved by the FDA and noted that protease-based drug-like small molecules can be used as potential inhibitors against SARS-CoV2.

Herbal treatments

The effectiveness of herbal treatment to control the contagious disease has been reported vastly in 2003 during severe acute respiratory syndrome (SARS) outbreak [26, 221]. By the Chinese medicine system, the application of herbal treatment is mainly guided by the type of herb (based on the catalog of classic literature on herbs) and the patient’s symptoms or signs [221]. However, in the case of viral diseases, enough information related to directly targeting the viral cause is not predetermined, consequently; the herbal treatment is generally not guided by viral pathology. The presence of potent antiviral properties in various plants would be greatly important in viral diseases especially in COVID-19 and as per the need of the patient and knowledge about target sites of different natural components; various herbs have been investigated for co-therapy in COVID-19 case [195]. Some of the natural compounds have been screened and confirmed to directly inhibit these important proteins in SARS or Middle East respiratory syndrome (MERS) coronavirus [128, 129, 152, 168, 196, 222]. The herbal treatment, as an accurate and proved method with high accuracy in many countries has been used to aid treatment. For herbs that contains the same effective formulas as QC and HQC, Vit D and Zinc QC, or HQC + Vit D + Zinc+anticoagulant+cortisone+breath aid (such as with the nebulizers) have proved very high cure percentage of infections in early and mid-stages of COVID-19 (Anonymous reviewer). Various reviews on COVID-19 and immunity boosting with the use of herbs have appeared [55]. Immunomodulatory effects of medicinal plants such as Tulsi / Ocimum sanctum, Cinnamomum zeylanicum, Zingiber officinale and Piper nigrum know since ancient time and has also been accepted by science, when these plants bear medicinal and cultural values. These are stimulated our kitchen and influenced what we ate in different seasons and the remedies we used for common ailments. Their immune-modulatory, antiviral, antioxidant, anti-inflammatory, anti-platelet, anti-atherosclerotic, hepato-protective, reno-protective properties; seems to be effective in immuno-regulation for controlling viral infections like COVID-19 [55]. There are various anti-viral metabolites have been reported from various sources, which also effective in controlling COVID-19, to providing immunity to the host and other complex mechanisms. A myriad of metabolites of the same capacity has been enlisted here (Table 1). Further pre-clinical and clinical trials need to be done for the evaluation of safety and efficacy of this polyherbal formulation.

Table 1 Herbal constituents with possible mechanisms to combat SARS-CoV-2 (Adopted and updated from [75, 76])

Antiviral drugs

Lopinavir/ ritonavir (Kaletra®) is used in combination with other medicines to treat adults and children over 14 days of age who are infected with human immunodeficiency virus HIV-1 [170]. Lopinavir/ritonavir among SARS-CoV patients has been associated with substantial clinical benefits (fewer adverse clinical outcomes) [27]. As per the guidelines of the National Health Commission of the People’s Republic of China, the combination of lopinavir and ritonavir is currently a recommended antivirus regimen in the latest version of diagnosis and treatment of pneumonia caused by SARS-CoV-2. The Lopinavir & Ritonavir affect proteolysis in the coronavirus replication cycle (Handbook of International Pulmonologists consensus on COVID-19, 2020). Four patients with mild or severe SARS-CoV-2 pneumonia had been cured or have significant improvement in their respiratory symptoms after treatment with combined lopinavir/ritonavir (Kaletra®), arbidol, and Shufeng Jiedu Capsule (SFJDC, a traditional Chinese medicine) on the base of supportive care [191].Japan’s anti-flu drug Favipiravir developed by a subsidiary of Fujifilm showed considerable results in clinical trials over 340 patients ( They found it safe & effective in the treatment of COVID-19 patients. Further investigations are recommended in this context. Arbidol is an antiviral drug used to cure influenza in Russia and China found effective against SARS-CoV-2 at a concentration range of 10–30 μM in vitro.

A study carried out on the discovery of new hydroxyethylamine analogs against 3CLpro protein target of SARS-CoV-2 via molecular docking, molecular dynamics simulation, and structure-activity relationship studies in antiviral drug section established the importance of using antiviral drugs, as evidenced by suitability as a strong candidate for therapeutic discovery against COVID-19 [94]. The treatment of viral infection, the use of antiviral agents, and the specific vaccination is most appropriate, but now; the effective treatment for COVID-19 is available with some antiviral drugs only. The possible drug target with the major stages of the COVID-19 virus in host cells is shown in Fig. 4 to understand about the possible actions of viral inhibition in human host systems. The antiviral drugs targeting the viral proteins (linked with enzymatic activities or blocking viral replication mechanisms) or host proteins (engaged in the viral life cycle, regulating immune system functioning, regulators of cellular processes) have more potential as almost all the viruses encode proteins specifically polymerases for replication and transcription. The drugs exhibiting polymerase inhibition are of two types, a) allosteric inhibitors; b) nucleoside, and nucleotide substrate analogs. Nucleosides after phosphorylation to triphosphates by host cells are converted to active nucleotide and then act inhibitor by competing with natural nucleoside triphosphate and consequently, terminate the growth of viral nucleic acids.

Fig. 4

Possible drug targeting sites for the repurposing of different drugs in SARS-CoV-2 along with major stages of the life cycle in host cells. Major stages of SARS-CoV-2 life cycle in host cells and the probable site of action of different drugs


Remdesivir, an antiviral agent initially used in Ebola virus clinical studies, revealed even more effective results against COVID-19 in vitro [191]. It is an adenosine analog, which incorporates into nascent viral RNA chains and results in premature termination. Further investigations of remdesivir are anticipated in human patients of COVID-19 on a priority basis. Although real-time therapy for COVID-19 is still in nutshell and not entirely any ‘magic bullet’ has introduced. In completed, ongoing and planned clinical trials, there are generic drugs promising therapies, prominently remdesivir [179]. Remdesivir is an analog of adenosine and is already known for the management of viral diseases. In the current scenario of this respiratory pandemic, remdesivir has overtaken on the other competitive drugs like hydroxychloroquine, chloroquine, lopinavir, and ritonavir in the context of its benefits over other lines of treatments [78, 127, 185]. In some of the trials, it has been observed that hydroxychloroquine and lopinavir or ritonavir showed little or no reduction in mortality of hospitalized COVID-19 patients, irrespective of standard care and management. However, yet in many countries, chloroquine or hydroxychloroquine being recommended as an option of COVID-19 treatment.

Remdesvir inhibits RNA-dependent-RNA-polymerase (RdRp) with its broad-spectrum antiviral activities against RNA viruses including SARS-CoV and MERS-CoV along with human CoV-229 E and CoV-OC43 replications [183]. Mentioned viral entities cause upper respiratory infection in children and its adults such as asthma, chronic obstructive pulmonary disease (COPD). Besides these, a member of δ coronavirus, pulmonary delta coronavirus (PDCoV) having the most divergent viral RdRp responsible for respiratory tract infections, which also treats using remdesivir [16]. The potency of remdesivir as an antiviral drug has also been proved by in silico test based on COVID-19’s RdRp built model [42]. Remdesevir selectively inhibits viral replication by targeting viral RdRp and inhibiting viral RNA synthesis followed by an efficient intracellular conversion into active triphosphate metabolites (NTPs). The RdRp amino acid sequences in SARS-CoV and MERS-CoV belonging to beta coronavirus of the B-linkages are up to 96% identical to SARS-CoV-2. Besides, MERS-CoV belonging to β coronavirus having C-linkages with only 71% identical with SARS-CoV-2 [5961]. The effective inhibition of RdRp of MERS-CoV by remdesivir is a bit complexed that it acts with triphosphate (RDV-TP) as substrate and compete with its natural protagonist ATP. The incorporation of nucleotide analog is more efficient to make changes in growing RNA chains. The inhibitor RDV does not cause immediate termination of chain and it allows the addition of more nucleotide due to the presence of 3′-hydroxyl prime free to cause Poly A tails. Afterward, RNA synthesis is arrested at 3′ position [5961]. Under in vitro studies, it is proved that remdesivir has the potentials to block SARS-CoV-2 even at a very low macromolecular concentration. On the other hand, in vivo model reflects a significant improvement in pulmonary pathology in MERS-CoV and SARS-CoV infected mice [161, 162].

In various clinical trials have been conducted on patients infected with SARS-CoV-2 with oxygen saturation below 94% (with/without oxygen support), the patients were treated with remdesivir (200 mg) intravenously for 10 days and from the first day (100 mg) daily over the next 9 days. The mortality rate during the study was found 18% among the patients receiving invasive ventilation and 5% among the patients not receiving invasive ventilation. During the follow up of the therapy, 68% of patients displayed an improved oxygen maintenance class. It was also observed that the risk of death was significantly increased in patients aged 70 years or older and among the patients with higher serum creatinine at baseline. 68% of patients showed clinical improvement and the risk ratio for patients receiving invasive oxygen in comparison to 2.78% of patients receiving non-invasive oxygen [62]. In another clinical trial, the results were clearer that the patients receiving remdesivir become recovered sooner than those receiving a placebo [7]. The European Medicines Agency recommends remdesivir positively for the treatment of SARS-CoV-2 [202]. However, in some cases, similar results have not been reported [194].

Grein et al. [62] noted the adverse effect during the compassionate use of remdesivir in patients with COVID-19. The symptoms include diarrhea, rash hypotension, abnormal liver function, and renal impairment. In 23% of patients of the study, serious adverse events like as acute kidney injury, septic shock, multi-organ failure were diagnosed. 8% of the patients discontinued the therapy due to severe adverse effects. The serious adverse events like acute kidney injury, septic shock, and multi-organ failure were observed in 8% of patients. According to another study reported by Wang et al. [194], the serious adverse effects were observed in 18% vs. 26% in remdesivir vs. control arm respectively; among remdesivir group, discontinued remdesivir (12%) compared to control (5%) was due to acute respiratory distress syndrome or respiratory failure in 5% patients of remdesivir group. In another clinical trial, the convalescent plasma therapy along with remdesivir has been proved beneficial in clinical trials [3]. Some precautions are required during the administration of remdesivir and no other evidence has been reported irrespective of nephrotoxicity. Remdesivir solution and lyophilized preparation (150 mg) contains 4.5–9.0 g expedient of sulfo-butyl-ether-β-cyclodextrin-sodium (SBECD). SBCED clears through the renal system and in some cases may cause moderate to severe renal impairment varying with individuals. In patients having glomerular filtration rate (GFR) ≥50% from baseline, close observation is required during remdesivir administration.

In the present scenario, no dose modifications of remdesivir have been recommended for patients suffering from mild and moderate renal impairment with COVID-19 besides causing severe renal impairment (eGFR< 30 ml/min) as a subside effect. Remdesivir cleaves by hydrolases and affects hepatic impairment is reported but few; reported to have subsided effects as influence alanine transferase (ALT) in patients with the upper limit of normal or severe hepatic function. No adverse effects on embryo-fetal development have been reported in a pregnant animal administered with remdesivir and on male fertility too. In COVID-19, the current recommendation of remdesivir doses is a bolus dose of 200 mg IV/ diluted in normal saline (0.9%) or 5% dextrose to be given over 60 min on day 1 followed by 100 mg IV to be given as diluted over 60 min for the next 5 days [166].

Chloroquine and hydroxychloroquine

The chemical structure of chloroquine (CQ) and hydroxychloroquine (HCQ) are closely related. CQ and HCQ have a chiral center, which produces two enantiomers R(−) or S(+) forms or isomers [80]. Most clinically used CQ and HCQ exist as a racemic mixture (50:50) of both isomers which complicates the understanding of their PK and associated toxicity as they could behave differently inside the body [15, 53, 80, 153]. Several studies have revealed that both drugs have antiviral activity in vitro through different mechanisms [79, 120, 164]. Different studies have reported the ability of CQ to inhibit viral entry [39, 58, 147], uncoating [12], assembly, and budding [49, 156]. One of the suggested mechanisms by which CQ can affect the entry step of viruses is by inhibiting quinone reductase-2 [96] and this enzyme is required for the biosynthesis of sialic acid [187]. Sialic acid is involved in virus attachment and entry into host cells by several viruses including HCoV-OC43 and MERS-CoV [107, 181]. CQ potently inhibits the entry of SARS-CoV into cells by interfering with the glycosylation of its cellular receptor angiotensin-converting enzyme 2 receptor (ACE2). SARS-CoV-2 also uses ACE2 as a receptor for cell entry and it suggests a possible similar effect of CQ on SARS-CoV-2 at this step of virus replication [72]. In the early stages, CQ can also affect virus replication by inhibiting virus-endosome fusionlikely via increasing endosomal pH [89]. CoVs such as SARS-CoV can enter target cells via a pH-dependent mechanism in which the acidic pH of the lysosome facilitates the fusion of the viral and endosomal membranes resulting in viral particle uncoating and subsequent release of viral nucleic acid into the cytoplasm [214]. Besides this, CQ can also impair post-translational modifications of viral proteins through interfering with proteolytic processes [143] and inhibition of glycosylation via specific interactions with sugarmodifying enzymes or glycosyltransferases [157]. Moreover, it has been suggested that CQ could affect the cytotoxic mechanisms and works as an anti-autophagy agent in vitro [57]. CQ also works as an anti-inflammatory agent through reducing tumor necrosis factor (TNFα) release and suppressing TNF receptors on monocytes [37, 157]. HCQ has a similar effect to CQ in interfering with the glycosylation of ACE2, blocking virus/cell fusion, and inhibiting lysosomal activity by increasing pH [106].

HCQ can also impede major histocompatibility complex (MCH) class II expression which inhibits T cell activation, expression of CD145, and cytokines release [114, 184, 206]. HCQ has been shown to impair Toll-like receptors (TLRs) signaling through increasing endosomal pH and interfering with TLR7 and TLR9 binding to their DNA/RNA ligands thereby inhibiting transcription of pro-inflammatory genes [47, 67, 95]. All the above said mechanisms including immunomodulatory effects of CQ and HCQ have raised the interest in using these drugs in COVID-19 patients at risk of cytokines release syndrome (CRS) [226]. It has also been studied that afteroral administration of CQ and HCQ, their bioavailability can reach up to 80% with plasma peak time around 2–4 h [65, 80, 178]. Thus, parenteral administration, if available, might be a better route especially that oral administration has shown huge inter-patient variability [14, 65, 177]. The long half-life of both CQ and HCQ (range from 30 to 60 days) is likely attributed to their large volume of distribution (200 to 800 L/kg) and extensive tissue uptake [6, 31, 41, 52, 74, 139, 197, 211].

In China 15 clinical trials were conducted to test the efficacy and safety of CQ or HCQ in the treatment of COVID-19, 8 of which were based on the administration of CQ, 6 were of HCQ, and another included both CQ and HCQ [220]. So far, in a clinical trial involving more than 100 patients, the chloroquine phosphate group showed efficacy in reducing the exacerbation of pneumonia, improving lung imaging findings, and increasing the negative rate of virus nucleic acid test. Given these findings, the Guidelines (version 6) for treatment of COVID-19 recommends for chloroquine phosphate administration by oral route at a dose of 500 mg (300 mg for chloroquine) for adults 2 times/ day (no more than 10 days) [40]. In a clinical trial based on Hydroxychloroquine’s therapeutic effect in COVID-19 in 20 patients after 1–2 days of HCQ treatment, clinical symptoms in all patients improved (NO: ChiCTR2000029559). After 5 days of HCQ treatment,19 patients improved on lung imaging findings. Besides, none of the mild patients had an exacerbation of disease in the HCQ group. Regarding safety, two of them had adverse reactions of mild rash and a slight headache, and the adverse reactions disappeared after adjusting the regimen. The results of this clinical trial confirmed the short-term efficacy of HCQ in the treatment of COVID-19, which can effectively improve lung imaging findings, promote a virus-negative conversion, and shorten the disease course. Although the number of cases in the HCQ group was relatively small, current data can provide insights for clinicians. The efficacy and safety of HCQ in the treatment of COVID-19 need to be confirmed in further preclinical and clinical trials (NO: ChiCTR2000029559). The dosing regimen of HCQ, CQ and others have also been investigated for COVID-19 as follows: Hydroxychloroquine-400 mg (BIDX 2 doses, then 200 mg BID for 5 days), Remdesivir-200 mg (IV loading dose, then 100 mg IV for 10 days), Oseltamivir-150 mg (BID for 5 days), Lopinavir- 400 mg (BID for 10 days) Ritonavir-100 mg (BID for 10 days) Ribavirin-2 g (loading dose, then 600 mg TID) [133]. A summary of the FDA [174] with the use of hydroxychloroquine and chloroquine to treat hospitalized patients with COVID-19 is now available. This includes reports of serious heart rhythm problems and other safety issues, including blood and lymph system disorders, kidney injuries, and liver problems and failure.


The syndromes caused by COVID-19 have been characterized by excessive production of inflammatory cytokines (interleukin (IL)-6, IL-10, and tumor necrosis factor-alpha (TNF-α) [24, 75, 76, 134, 163]. Hence, anti-cytokine therapy has been suggested as a treatment of COVID-19, although its safety and efficacy in this population is yet to be established [119]. Tocilizumab, an immunosuppressive agent, has also been found to be effective in vivo in COVID- 19 patients in China [208]. Tocilizumab is an FDA-approved IL-6 receptor antagonist commonly used to treat CRS secondary to CAR (chimeric antigen receptor) T-cell therapy [51]. Tocilizumab is theorized to treat the CRS that can occur in COVID-19 patients like its use in cytokine release syndrome (CRS) secondary to chimeric antigen receptor (CAR) T-cell therapy [224]. In two cases of COVID-19-induced CRS with elevated IL-6 levels and progression to sHLH (cytopenias, hypertriglyceridemia, elevated ferritin & LDH, hypofibrinogenemia), the treatment with tocilizumab has been found effective [138]. Evidence suggests a deficient T-cell response underlies the severity of COVID-19. CD8 and CD4 T cell levels are decreased in COVID-19 patients and correlate with the severity of disease [22]. Moreover, diabetes, which is associated with T-cell mediated immunosuppression, is a risk factor for COVID-19 [138]. IL-6 promotes immature thymocyte differentiation into cytotoxic T-cells and is needed for B-cell production of IgM and IgG. Thus, elevated IL-6 levels may be a compensatory mechanism for an impaired viraldirected cytotoxic T-cell response. Thus, decreasing IL-6 levels in COVID-19 may promote increased viral replication if tocilizumab is used too early in the disease course. A retrospective study has been performed to observe the efficacy of tocilizumab in treating severe or critical COVID-19 patients. Along with the basic anti-virus treatment, TCZ 400 mg was applied once to 20 patients intravenously. Within a few days, 75.0% improved oxygenation,the fever returned to normal and other symptoms improved remarkably. Besides, the opacity lung lesion on CT scans absorbed in 90.5% patients and the percentage of peripheral lymphocytes returned to normal in 52.6% patients. Their data suggests TCZ might be an effective treatment in severe patients of COVID-19 [220].

However, there is currently no data from rigorously conducted clinical trials evaluating tocilizumab use in COVID-19. Many clinical trials are actively recruiting subjects to determine the safety and efficacy of tocilizumab in the treatment of severe COVID-19 pneumonia in adult patients (NCT04315480, NCT04317092, NCT04320615, ChiCTR2000029765) [138]. These clinical trials may further elucidate tocilizumab’s effects on COVID-19-induced organ failure and mortality and correlate these outcomes with inflammatory marker trends.


Although there is no role for antibiotics in the treatment of coronavirus infection, 58% of patients in Wuhan were started on antibiotics [63]. Further, the use of empiric antibiotics is endorsed by the WHO to cover bacterial superinfections. It can be efficacious to treat COVID-19 patients provided that adequate clinical trials are conducted. The macrolide antibiotic-Bafilomycin A1 can be a promising candidate to treat the novel COVID-19. It is an endo/lysosomal V-ATPase inhibitor which mainly interrupts the function of ACE2. The ACE2 is mainly involved in SARS-CoV and SARS-CoV-2 infection by acting as a viral receptor, by which it may stop the viral cycle at the emerging stage itself [190]. Nitazoxanide is used to treat parasitic infections which were also found to be effective in treating a wide range of viruses including human coronaviruses in vitro at very low concentrations. It selectively blocks the viral hemagglutinin intracellular trafficking and insertion of this protein into the host plasma membrane. One more antibiotic which was found to be effective in viral infections is Azithromycin (a macrolide antibacterial). The drug effectively inhibits the growth of the Zika virus and the Ebola virus in-vitro [13, 116]. The synergistic effects of azithromycin and hydroxychloroquine combination were also reported to treat COVID-19 patients [56].

The report finding highlights the efficiency of this combination in clearing viral nasopharyngeal carriage within a short time in Covid-19 patients when compared to patients receiving only hydroxychloroquine. The hydroxychloroquine increases the pH withinacidic organelles and inhibits the entry of the virus [30, 146], producing antiviral effect (explained earlier) while the exact anti-viral action of Azithromycin is not known. It may have immunomodulatory properties that might be beneficial in the treatment of pulmonary viral infections. The molecule may decrease the inflammatory responses and production of excessive cytokine accompanying viral infections. The immunomodulatory mechanisms may be due to decreasing chemotaxis of neutrophils to the lungs by inhibiting cytokines and the formation of reactive oxygen species [56, 87]. Worldwide, Hydroxychloroquine along with antivirals (Lopinavir & Ritonavir) are being used to treat COVID-19 patients.

Anti-inflammatory agents

There is a dilemma of anti-inflammatory therapy, balancing the risk and benefit ratio is a critical issue. The main concern is that anti-inflammatory medications, such as corticosteroid may delay the elimination of viruses and increase the risk of secondary infection, especially in those with an impaired immune system. Secondly, biological agents targeting pro-inflammatory cytokines can only inhibit specific inflammatory factor, and thus may not be very effective in curbing the CS in COVID-19 in which other cytokines maybe significant. Thirdly, some anti-inflammation medication such as JAK inhibitors also block INF-a production, which is important in fighting viruses, and theoretically may not be suitable for the treatment of inflammatory CS caused by viruses as COVID-19.


Numerous clinical studies have reported the efficacy of glucocorticoids in the treatment of coronavirus pneumonia (such as SARS and MERS) or influenza pneumonia, but no consensus has been reached. Timely usage of glucocorticoids could improve the early fever, promote absorption of pneumonia, and obtain better oxygenation. However, some studies didn’t show beneficial effects with glucocorticoid, or even adverse reactions or delayed virus clearance, leading to a reduction in disease severity [5, 70, 210]. At present, systemic glucocorticoid administration was empirically used for severe complications to suppress CS manifestations in patients with COVID-19, such as ARDS, acute heart injuries, acute kidney complications, and patients with higher D-dimer levels [21, 75, 76, 173]. Chen et al. [23] reported 19 (19%) patients were treated with glucocorticoids for 3–15 days (median 5; 3–7 days), and methylprednisolone (1–2 mg/kg per day) are recommended for patients with ARDS, for as short a duration of treatment as possible. Wang et al. [191] reported 44.9% of patients of COVID-19 were given glucocorticoid therapy and no effective outcomes were observed. Russell et al. [150] reported clinical evidence did not support corticosteroid treatment for COVID-19 lung injury.

JAK inhibitors

The ACE-2 is the receptors for novel coronavirus pneumonia (SARS-CoV-2) is a cell-surface protein widely existed on cells in the heart, kidney, blood vessels, especially lung AT2 alveolar epithelial cells. SARS-CoV-2could invade and enter cells through endocytosis. One of the known regulators of endocytosis is the AP2-associated protein kinase 1 (AAK1). AAK1 inhibitors can interrupt the passage of the virus into cells and can help prevent virus infections. Baricitinib, a JAK inhibitor as well as an AAK1 inhibitor, was suggested a possible candidate for the treatment of COVID-19, considering its relative safety and high affinity. Therapeutic dosage with either 2 mg or 4 mg once daily was enough to reach the plasma concentration of inhibition [98]. The biggest concern about JAK inhibitors is that it can inhibit a variety of inflammatory cytokines including INF-a, which plays an important role in curbing virus activity. Further clinical trials and detailed analysis are warranted to confirm their efficacy. To date, there are some registered clinical trials of JAK inhibitor: “Study for safety and efficacy of Jakotinib hydrochloride tablets in the treatment severe and acute exacerbation patients of novel coronavirus pneumonia (COVID-19)” (ChiCTR2000030170); “Severe novel coronavirus pneumonia (COVID-19) patients treated with ruxolitinib in combination with mesenchymal stem cells: a prospective, single-blind, randomized controlled clinical trial” (ChiCTR2000029580).

Vitamin C

Ascorbic acid (Vitamin C) consists of antioxidant properties. It is not having a direct lethal effect on viruses, but it was reported that viral respiratory infections in human beings are affected by the levels of vitamin C [69]. When infection occurs, the cytokine surge caused by infection is activated and neutrophils get accumulated in the lungs, destroying alveolar capillaries. Early clinical studies have shown that vitamin C is having the potential to inhibit these processes. Combining Ascorbic acid with other drugs will be helpful for affected COVID-19 individuals [148].


Baricitinib is another drug that is used in the treatment of rheumatoid arthritis. It can be also used to treat novel coronavirus [145]. It might target the endocytosis process. The receptor that SARS-CoV-2 uses to infect lung cells might be ACE2, which are prone to viral infection. The AP2-associated protein kinase 1 (AAK1) might be one of the known regulators of endocytosis. Disruption of AAK1 might interrupt the passage of the virus into cells and the intracellular assembly of virus particles [115].

Vaccine development

Vaccination is the most effective way to prevent influenza infection now. However, the high genetic variability of the virus renders the protection incomplete. In the case of the probability of the risk, some of the effective measures are to be adopted such as measurement or early detection, isolation and treatment of cases, as well as minimization of transmission through social interaction. The disease has no vaccine and no treatment in the recent scenario, forcing health authorities to resort to control tools dating back to the earliest days of empirical microbiology: isolation and quarantine. Many of the patients having strong immunity, can resist the lethality of the viruses and in the case of coronavirus, acquire immunity is delayed and therefore respiratory illness prevails before the immunity development and ability to survive to the infection. A viral vaccine can be developed by live-attenuated viruses, whole-killed viruses, split (proteins) viruses, recombinant subunits, virus-like particles etc. (Fig. 5). The scientist community is doing homework at full swing to create effective and safe vaccines. The efforts to develop a vaccine by various leading biotech companies, universities, and research agencies/institutions are underway. More than 90 and about reaching century vaccines are underway to be developed by various leading companies and universities across the world [17]. Scientists have trialed different methodologies, techniques, and efforts to a licensed their vaccines. At least six groups have already their human trials and started injecting formulations into volunteers’ arms under safety measures. As per the report published in July 2020 from the account of the ChAdOx1 nCoV-19 vaccine’sdeveloper, briefed about its immunogenicity and safety, as a result of phase 1 and 2. This way taking lead in amongst all runners world-wide [50]. In a vaccine race, a coronavirus vaccine shows lasting benefits in the people were front runner of COVID-19 vaccine trials, as they were reported to have high value of potent antibodies effective against coronavirus on and after the 4 months of their jab. Vaccine developed by Biotech from Moderna in Cambridge, Massachusetts has reported 94% effectiveness in their vaccine to cure COVID-19 [201].

Fig. 5

Possible types of viral vaccines can be developed for COVID-19

COVID-19 management

COVID-19 had become a pandemic, Globally, as of 5:02 pm CET, 11 December 2020, there have been 69,143,017 confirmed cases of COVID-19, including 1,576,516 deaths, reported to WHO ( The WHO and the United States Centre for Disease Control (CDC) have issued preliminary guidelines about diagnosis and disease control. But limited guidelines are available regarding the treatment of infected individuals due to lack of information about disease pathogenesis and non- availability of vaccine or specific anti-viral drugs for the treatment of the infected and critically ill patients. To control the COVID19 spread WHO, NIH and CDC and other scientific bodies releasing their guidelines, which can be concluded as, “Physical distancing with others is the best way to reduce the spread of coronavirus disease”. Primarily asymptomatic patients, with travel history or in contact with someone who has traveled recently are required to isolate themselves and undergo RT- PCR tests for Covid-19. The countries suffering from COVID19 banned social gatherings like in parks, marriages, restaurants, shops, and any other places [199]. Work from home culture was following by various bodies other than essential services. Self-isolation is an important measure taken by those who have COVID-19 symptoms to avoid infecting others in the community, including family members [106]. National Institutes of Health (NIH) published guidelines on prophylaxis use, testing, and management of patients with COVID19 based on scientific evidence and patient data. NIH appointed a panel to develop the guidelines for COVID19 control and treatment. Panel members include representatives from federal agencies, health care, and professional societies based on their clinical experience and expertise in patient management. Health care system declares step to step guidelines surpass management and prevention of COVID19 such as infection control guidance, protocols for using PPE, hand hygiene, discontinuing transmission-based precautions, post-mortem guidance and other guidance by facility type as alternate care sites, ambulatory care settings, assisted living facilities, pharmacies, and nursing home and long term care facilities. The spreadsheets & guidance release by health care units will help to maintain safety measures during the planning of the health care facilities and will optimize the transmission of coronavirus disease. Medical professionals caring for patients with coronavirus disease in 2019 are at high risk of contracting the infection [28].

It is inevitable to ensure health care professional safety not only to provide their services to patients but also to ensure the transmission of the virus to others [21]. World health organization has released guidelines for doctors and other health care professionals to deal with COVID19. They conducted training and webinars for physicians and nursing personnel on the management of patients with COVID19 and septic shock, ventilation strategy, management of aerosol-generating medical procedure, infection & prevention control practices, and psychological care of patients. Department of Health Research and ICMR recommended the use of hydroxychloroquine for prophylaxis of COVID 19 infection for the high-risk populations including all asymptomatic health care workers involved in the care of suspected or confirmed cases of COVID19. WHO guidance on specimen collection, processing, and laboratory testing is available [199]. The Panel recommends carefully monitoring, evaluating, and treating hospitalized patients with COVID19 for the incident and other serious events when indicated. Most people with COVID19 develop the only mild or uncomplicated illness, approximately 14% develop a severe disease that requires hospitalization and oxygen support, and 5% require admission to an intensive care unit. Patients with a mild clinical presentation (absence of viral pneumonia and hypoxia) may not initially require hospitalization, and many patients will be able to manage their illness at home. All findings suggested taking aggressive measures such as the use of masks, goggles, avoid social gatherings and follow other safety measures to ensure the safety during COVID19 outbreak especially when limited information about the transmission and infective potency of the virus is available.


The very turn of the year 2020 took the whole world by storm as a novel Coronavirus first originated in the Wuhan town of China. In this continuation, a detailed and highly plausible package of current knowledge has been put forwarded in the form review demonstrating the virology, pathophysiology, genomics, and structure, and drug repurposes along with management of SARS-CoV-2.The increment of cases on a very fast move is providing a wider horizon to study biological interventions caused by SARS-CoV-2 in humans. We foresee the future emergence of novel virus variants or strains, to facilitate a sustainable life on the planet earth. Except for a few island nations, every country worldwide has been affected by the novel SARS-COV-2, thus declared as a pandemic. Since there is no FDA approved vaccine to COVID-19 by far, several alternative treatments and precautionary measures are explored to find a stable treatment for this disease. Most of these treatments and vaccines are assertive and based on the symptomatic suppression of the disease. In sum, we tried to provide key insights into SARS-CoV-2 and filling some gaps and uncertainties arise in certain points of this knowledge dissemination. It is clear more research still needs to be conducted to get a more detailed insight.

Availability of data and materials

All the data will be available whenever required.



Severe Acute Respiratory Syndrome Coronavirus


Corona Virus Disease


Angiotensin-converting enzyme 2


World health organization






Real Time- Polymerase Chain Reaction


Severe Acute Respiratory Syndrome


Middle East Respiratory disease

PLpro :

Papain-like protease

3CLpro :

3C-like protease


Human Immunodeficiency Virus


Chimeric antigen receptor


Receptor-binding domain


Receptor-binding motif


Human Corona Virus


Priming response by host serine protease


Open reading frame

HE protein:



Ribonucleotide protein


Rough endoplasmic reticulum


Endoplasmic reticulum-Golgi intermediate compartment


Antigen presentation cells


Cytotoxic T lymphocytes


Major histocompatibility complex


Human leukocyte antigen


Reverse transcription-polymerase chain reaction


Bronchoalveolar lavage fluid






Tumor necrosis factor






Monocyte chemoattractant protein-1


Macrophage inflammatory protein


Food and Drug Administration (USA)


Shufeng Jiedu Capsule


Chronic obstructive pulmonary disease


Pulmonary delta coronavirus




Remdesiv triphosphate




Glomerular filtration rate


Toll-like receptors


Cytokines release syndrome


Jakotinib hydrochloride


AP2-associated protein kinase 1


  1. 1.

    Aceto GM, Solano AR, Neuman MI, Veschi S, Morgano A, Malatesta S, et al. High-risk human papilloma virus infection tumor pathophenotypes and BRCA1/2 and TP53 status in juvenile breast cancer. Breast Cancer Res Treat. 2010;122(3):671–83.

    PubMed  Article  PubMed Central  Google Scholar 

  2. 2.

    Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nat Med. 2020;26(4):450–2.

    CAS  Article  Google Scholar 

  3. 3.

    Anderson J, Schauer J, Bryant S, Graves CR. The use of convalescent plasma therapy and remdesivir in the successful management of a critically ill obstetric patient with novel coronavirus 2019 infection: a case report. Case Rep Women’ Health. 2020;27:e00221.

    Article  Google Scholar 

  4. 4.

    Arabi YM, Alothman A, Balkhy HH, et al. Treatment of middle east respiratory syndrome with a combination of lopinavir-ritonavir and interferon-beta1b (MIRACLE trial): study protocol for a randomized controlled trial. 2018;19(1):81.

  5. 5.

    Auyeung TW, Lee JS, Lai WK, Choi CH, Lee HK, Lee JS, et al. The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study. J Inf Secur. 2005;51:98–102.

    Google Scholar 

  6. 6.

    Banks CN. Melanin: blackguard or red herring? Another look at chloroquine retinopathy. Aust N Z J Ophthalmol. 1987;15:365–70.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  7. 7.

    Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of COVID-19 – preliminary report. N Engl J Med NEJM. 2020:oa2007764.

  8. 8.

    Belouzard S, Chu VC, Whittaker GR. Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. Proc Natl Acad Sci U S A. 2009;106:5871–6.

    Article  PubMed  PubMed Central  Google Scholar 

  9. 9.

    Belouzard S, Millet JK, Licitra BN, Whittaker GR. Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses. 2012;4(6):1011–33.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  10. 10.

    Berry M, Gamieldien J, Fielding BC. Identification of new respiratory viruses in the new millennium. Viruses. 2015;7(3):996–1019.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  11. 11.

    Bhoj VG, Chen ZJ. Ubiquitylation in innate and adaptive immunity. Nature. 2009;458(7237):430–7.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  12. 12.

    Bishop NE. Examination of potential inhibitors of hepatitis a virus uncoating. Intervirology. 1998;41:261–71.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  13. 13.

    Bosseboeuf E, Aubry M, Nhan T, de Pina JJ, Rolain JM, Raoult D, et al. Azithromycin inhibits the replication of Zika virus. J Antiviral Antiretroviral. 2018;10(1):6–11.

    Article  Google Scholar 

  14. 14.

    Bothwell B, Furst DE. Hydroxychloroquine. In: Antirheumatic therapy: actions and outcomes. Springer, Birkhäuser Basel. 2005:81–92.

  15. 15.

    Brocks DR, Mehvar R. Stereoselectivity in the pharmacodynamics and pharmacokinetics of the chiral antimalarial drugs. Clin Pharmacokinet. 2003;42:1359–82.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  16. 16.

    Brown AJ, Won JJ, Graham RL, Dinnon KH III, Sims AC, Feng JY, et al. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic delta coronaviruses with a highly divergent RNA dependent RNA polymerase. Antivir Res. 2019;169(2019):104541.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  17. 17.

    Callaway E. The race for coronavirus vaccines: a graphical guide. Nature. 2020;580(7805):576.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  18. 18.

    Cavanagh D. The coronavirus surface glycoprotein. In: Siddell SG, editor. The coronaviridae. Boston: Springer; 1995. p. 73–113.

    Google Scholar 

  19. 19.

    CDC. Interim guidelines for collecting handling and testing clinical specimens for COVID-19. Laboratories. USA: Centers for Disease Control and Prevention, USA Gov. 2020. (Accessed on 09.07.2020).

  20. 20.

    Chan JF, Chan KH, Kao RY, To KK, Zheng BJ, Li CP, et al. Broad-spectrum antivirals for the emerging middle east respiratory syndrome coronavirus. J Inf Secur. 2013;67(6):606–16.

    Google Scholar 

  21. 21.

    Chan KW, Wong VT, Tang SCW. COVID-19: an update on the epidemiological clinical preventive and therapeutic evidence and guidelines of integrative Chinese-Eestern medicine for the management of 2019 novel coronavirus disease. Am J Chin Med. 2020;48(03):737–62.

    CAS  PubMed  Article  Google Scholar 

  22. 22.

    Chen G, Wu D, Guo W, et al. Clinical and immunologic features in severe and moderate coronavirus disease 2019. medRxiv. 2020b.

  23. 23.

    Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan China: a descriptive study. Lancet. 2020c;395:507–13.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  24. 24.

    Chen RC, Tang XP, Tan SY, Liang BL, Wan ZY, Fang JQ, et al. Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience. Chest. 2006;129:1441–52.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  25. 25.

    Chen Y, Liu Q, Guo D. Emerging coronaviruses: genome structure replication and pathogenesis. J Med Virol. 2020a;92:418–23.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  26. 26.

    Chen Z, Nakamura T. Statistical evidence for the usefulness of Chinese medicine in the treatment of SARS. Phytother Res. 2004;18(7):592–4.

    PubMed  Article  Google Scholar 

  27. 27.

    Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59:252–6.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  28. 28.

    Chung M, Bernheim A, Mei X, et al. CT imaging features of 2019 novel coronavirus (2019- nCoV). Radiology. 2020;200230.

  29. 29.

    Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet. 2003;361:2045–6.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  30. 30.

    Colson P, Rolain JM, Raoult D. Chloroquine for the 2019 novel coronavirus SARSCoV-2. Int J Antimicrob Agents. 2020;55(3):105923.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  31. 31.

    Cutler DJ, MacIntyre AC, Tett SE. Pharmacokinetics and cellular uptake of 4-aminoquinoline antimalarials. Agents Actions Suppl. 1988;24:142–57.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  32. 32.

    Davis L. Proteins. 2003;50:437.

    PubMed  Article  CAS  PubMed Central  Google Scholar 

  33. 33.

    de Haan CA, de Wit M, Kuo L, Montalto-Morrison C, Haagmans BL, Weiss SR, et al. The glycosylation status of the murine hepatitis coronavirus M protein affects the interferogenic capacity of the virus in vitro and its ability to replicate in the liver but not the brain. Virology. 2003;312(2):395–406.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  34. 34.

    de Haan CA, Rottier PJ. Molecular interactions in the assembly of coronaviruses. Adv Virus Res. 2005;64:165–230.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  35. 35.

    de Haan CA, Vennema H, Rottier PJ. Assembly of the coronavirus envelope: homotypic interactions between the M proteins. J Virol. 2000;74(11):4967–78.

    PubMed  PubMed Central  Article  Google Scholar 

  36. 36.

    de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJ, Chau TN, et al. Fatal outcome of human influenza a (H5N1) is associated with high viral load and hypercytokinemia. Nat Med. 2006;12:1203–7.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  37. 37.

    de Sá MS, Costa JFO, Krettli AU, Zalis MG, de Azevedo Maia GL, Sette IMF, et al. Antimalarial activity of betulinic acid and derivatives in vitro against Plasmodium falciparum and in vivo in P. berghei-infected mice. Parasitol Res. 2009;105(1):275.

    Article  PubMed  PubMed Central  Google Scholar 

  38. 38.

    de Wit E, van Doremalen N, Falzarano D, et al. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14:523–34.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  39. 39.

    Diaz-Griffero F, Hoschander SA, Brojatsch J. Endocytosis is a critical step in entry of subgroup B avian leukosis viruses. J Virol. 2002;76:12866–76.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  40. 40.

    Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020;14:58–60.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  41. 41.

    Ducharme J, Farinotti R. Clinical pharmacokinetics and metabolism of chloroquine: focus on recent advancements. Clin Pharm. 1996;31:257–74.

    CAS  Article  Google Scholar 

  42. 42.

    Elfiky AA. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci. 2020;248(2020):117477.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  43. 43.

    Enjuanes L, Brian D, Cavanagh D, Holmes K, Lai MMC, Laude H et al. (2000) Coronaviridae. In: Murphy M.A. et al. (eds.) Virus taxonomy classification and nomenclature of viruses. Academic, New York pp. 835-849.

  44. 44.

    Enmozhi SK, Raja K, Sebastine I, Joseph J. Andrographolide as a potential inhibitor of SARS-CoV-2 main protease: an in-silico approach. J Biomol Struct Dyn. 2020;2020:1–10.

    CAS  Article  Google Scholar 

  45. 45.

    Escors D, Ortego J, Enjuanes L. The membrane M protein of the transmissible gastroenteritis coronavirus binds to the internal core through the carboxy-terminus. In: Lavi E, et al., editors. The Nidoviruses. Boston: Springer; 2001a. p. 589–93.

    Google Scholar 

  46. 46.

    Escors D, Ortego J, Laude H, Enjuanes L. The membrane M protein carboxy terminus binds to transmissible gastroenteritis coronavirus core and contributes to core stability. J Virol. 2001b;75(3):1312–24.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  47. 47.

    Ewald SE, Lee BL, Lau L, Wickliffe KE, Shi GP, Chapman HA, et al. The ectodomain of toll-like receptor 9 is cleaved to generate a functional receptor. Nature. 2008;456:658–62.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  48. 48.

    Fan W, Su Z, Bin Y, Yan MC, Wen W, Zhi GS, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265–9.

    CAS  Article  Google Scholar 

  49. 49.

    Ferreira DF, Santo MP, Rebello MA, Rebello MC. Weak bases affect late stages of Mayaro virus replication cycle in vertebrate cells. J Med Microbiol. 2000;49:313–8.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  50. 50.

    Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020.

  51. 51.

    Frey N, Porter D. Cytokine release syndrome with chimeric antigen receptor T cell therapy. Biol Blood Marrow Transplant. 2019;25(4):e123–7.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  52. 52.

    Frisk-Holmberg M, Bergqvist Y, Termond E, Domeij-Nyberg B. The single dose kinetics of chloroquine and its major metabolite desethylchloroquine in healthy subjects. Eur J Clin Pharmacol. 1984;26:521–30.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  53. 53.

    Furst DE. Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. Lupus. 1996;5:11–5.

    Article  Google Scholar 

  54. 54.

    Gallagher TM, Buchmeier MJ. Coronavirus spike proteins in viral entry and pathogenesis. Virology. 2001;279(2):371–4.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  55. 55.

    Gautam S, Gautam A, Chhetri S, Bhattarai U. Immunity against COVID-19: potential role of Ayush Kwath. J Ayur Integ Med. 2020.

  56. 56.

    Gautret P, Lagier JC, Parola P, Meddeb L, Mailhe M, Doudier B, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;105949.

  57. 57.

    Golden EB, Cho HY, Hofman FM, Louie SG, Schönthal AH, Chen TC. Quinoline-based antimalarial drugs: a novel class of autophagy inhibitors. Neurosurg Focus. 2015;38:e12.

    Article  PubMed  PubMed Central  Google Scholar 

  58. 58.

    Gonzalez-Dunia D, Cubitt B, de la Torre JC. Mechanism of Borna disease virus entry into cells. J Virol. 1998;72:783–8.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  59. 59.

    Gordon CJ, Tchesnokov EP, Feng JY, Porter DP, Götte M. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J Biol Chem. 2020a;295(2020):4773–9.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  60. 60.

    Gordon CJ, Tchesnokov EP, Woolner E, Perry JK, Feng JY, Porter DP, et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem. 2020b.

  61. 61.

    Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, O'meara MJ, et al. A SARS-CoV-2-human protein-protein interaction map reveals drug targets and potential drug-repurposing. BioRxiv. 2020c.

  62. 62.

    Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate use of remdesivir for patients with severe COVID-19. N Engl J Med. 2020;382(24):2327–36.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  63. 63.

    Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  64. 64.

    Guo Y, Cao Q, Hong ZS, et al. The origin transmission and clinical therapies on coronavirus disease 2019 (coVid-19) outbreak - an update on the status. Mil Med Res. 2020;7:11.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  65. 65.

    Gustafsson LL, Walker O, Alvan G, Beermann B, Estevez F, Gleisner L, et al. Disposition of chloroquine in man after single intravenous and oral doses. Br J Clin Pharmacol. 1983;15:471–9.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  66. 66.

    Guy JS. Turkey coronavirus is more closely related to avian infectious bronchitis virus than to mammalian coronaviruses: a review. Avian Pathol. 2000;29(3):207–12.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  67. 67.

    Hacker H, Mischak H, Miethke T, Liptay S, Schmid R, Sparwasser T, et al. CpG-DNAspecific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. EMBO J. 1998;17:6230–40.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  68. 68.

    Hajeer AH, Balkhy H, Johani S, et al. Association of human leukocyte antigen class II alleles with severe Middle East respiratory syndrome-coronavirus infection. Ann Thorac Med. 2016;11:211–3.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  69. 69.

    Hemilä H, Douglas RM. Vitamin C and acute respiratory infections. Int J Tuberc Lung Dis. 1999;3:756–61.

    PubMed  PubMed Central  Google Scholar 

  70. 70.

    Ho JC, Ooi GC, Mok TY, Chan JW, Hung I, Lam B, et al. High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome. Am J Respir Crit Care Med. 2003;168:1449–56.

    PubMed  Article  Google Scholar 

  71. 71.

    Ho TY, Wu SL, Chen JC, Li CC, Hsiang CY. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction. Antivir Res. 2007;74(2007):92–101.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  72. 72.

    Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. SARSCoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280.e8.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  73. 73.

    Hogue BG, Machamer CE. Coronavirus structural proteins and virus assembly. In: Perlman S, et al., editors. Nidoviruses: American society of microbiology; 2007. p. 179–200.

    Google Scholar 

  74. 74.

    Hovorka R, Powrie JK, Smith GD, Sonksen PH, Carson ER, Jones RH. Five-compartment model of insulin kinetics and its use to investigate action of chloroquine in NIDDM. Am J Phys. 1993;265:e162–75.

    CAS  Google Scholar 

  75. 75.

    Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan China. Lancet. 2020a;395(10223):497–506.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  76. 76.

    Huang F, Li Y, Leung EL-H, Liu X, Liu K, Wang Q, et al. A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19). Pharmacol Res. 2020b;158:e104929.

    CAS  Article  Google Scholar 

  77. 77.

    Hulswit RJG, Lang Y, Bakkers MJG, Li W, Li Z, Schouten A, et al. Human coronaviruses OC43 and HKU1 bind to 9-O-acetylated sialic acids via a conserved receptor-binding site in spike protein domain a. Proc Natl Acad Sci U S A. 2019;116:2681–90.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  78. 78.

    IDSA. Infectious Diseases Society of America: infectious diseases society of America guidelines on the treatment and management of patients with COVID-19; 2020. (Published by IDSA, 4/11/2020) (Accessed on 29.08.2020).

    Google Scholar 

  79. 79.

    Inglot AD. Comparison of the antiviral activity in vitro of some non-steroidal antiinflammatory drugs. J GenVirol. 1969;4:203–14.

    CAS  Google Scholar 

  80. 80.

    Iredale J, Fieger H, Wainer IW. Determination of the stereoisomers of hydroxychloroquine and its major metabolites in plasma and urine following a single oral administration of 44 racemic hydroxychloroquine. Semin Arthritis Rheum. 1993;23:74–81.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  81. 81.

    Isaacson MK, Ploegh HL. Ubiquitination ubiquitin-like modifiers and deubiquitination in viral infection. Cell Host Microbe. 2009;5(6):559–70.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  82. 82.

    Iwasaki A, Pillai PS. Innate immunity to influenza virus infection. Nat Rev Immunol. 2014;14:315–28.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  83. 83.

    Jin D, Zheng B. Roles of spike protein in the pathogenesis of SARS coronavirus. Hong Kong Med J. 2009;15(Suppl 2):37–40 url: (Accessed on 07.11.2020).

    PubMed  PubMed Central  Google Scholar 

  84. 84.

    Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y. Structure-based drug design,virtual screening and high-throughput screening rapidly identify antiviral leads targeting COVID-19. BioRxiv. 2020.

  85. 85.

    Joshi RS, Jagdale SS, Bansode SB, Shankar SS, Tellis MB, Pandya VK, et al. Discovery of potential multi-target-directed ligands by targeting host-specific SARS-CoV-2 structurally conserved main protease. J Biomol Struct Dyn. 2000;2020:1–16.

    CAS  Article  Google Scholar 

  86. 86.

    Kammila S, Das D, Bhatnagar PK, Sunwoo HH, Zayas-Zamora G, King M, et al. A rapid point of care immunoswab assay for SARS-CoV detection. J Virol Methods. 2008;152(1–2):77–84.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  87. 87.

    Kanoh S, Rubin BK. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev. 2010;23:590–615 PMID: 20610825.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  88. 88.

    Khailany RA, Safdar M, Ozaslan M. Genomic characterization of a novel SARS-CoV-2. Gene Rep. 2020;19:100682.

    Article  PubMed  PubMed Central  Google Scholar 

  89. 89.

    Khan M, Santhosh SR, Tiwari M, Lakshmana Rao PV, Parida M. Assessment of in vitro prophylactic and therapeutic efficacy of chloroquine against Chikungunya virus in vero cells. J Med Virol. 2010;82:817–24.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  90. 90.

    Knoops K, Kikkert M, van den Worm SH, Zevenhoven-Dobbe JC, van der Meer Y, Koster AJ, et al. SARS-coronavirus replication is supported by a reticulovesicular network of modified endoplasmic reticulum. PLoS Biol. 2008;6(9):e226.

    Article  PubMed  PubMed Central  Google Scholar 

  91. 91.

    Kuba K, Imai Y, Ohto-Nakanishi T, et al. Trilogy of ACE2: a peptidase in the renin-angiotensin system a SARS receptor and a partner for amino acid transporters. Pharmacol Ther. 2010;128:119–28.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  92. 92.

    Kumar D, Chandel V, Raj S, Rathi B. In silico identification of potent FDA approved drugs against coronavirus COVID-19 main protease: a drug repurposing approach. Chem Biol Lett. 2020a;7(3):166–75.

    Google Scholar 

  93. 93.

    Kumar M, Mazur S, Ork BL, Postnikova E, Hensley LE, Jahrling PB, et al. Inactivation and safety testing of Middle East respiratory syndrome coronavirus. J Virol Methods. 2015;223:13–8.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  94. 94.

    Kumar S, Sharma PP, Shankar U, Kumar D, Joshi SK, Pena L, et al. Discovery of new hydroxyethylamine analogs against 3CLpro protein target of SARS-CoV-2: molecular docking, molecular dynamics simulation and structure-activity relationship studies. J Chem Inf Model. 2020b.

  95. 95.

    Kuznik A, Bencina M, Svajger U, Jeras M, Rozman B, Jerala R. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol. 2011;186:4794–804.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  96. 96.

    Kwiek JJ, Haystead TA, Rudolph J. Kinetic mechanism of quinone oxidoreductase 2 and its inhibition by the antimalarial quinolines. Biochemistry. 2004;43:4538–47.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  97. 97.

    Lai MMC, Cavanagh D. The molecular biology of coronaviruses. Adv Virus Res. 1997;48:1–100.

  98. 98.

    Lajoie J, Mwangi L, Fowke KR. Preventing HIV infection without targeting the virus: how reducing HIV target cells at the genital tract is a new approach to HIV prevention. AIDS Res Ther. 2017;14:46.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  99. 99.

    Laude H, Masters PS. The coronavirus nucleocapsid protein. In: Siddell SG, editor. The coronaviridae. Boston: Springer; 1995. p. 141–63.

    Google Scholar 

  100. 100.

    Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med. 2020;172(9):577–82.

    PubMed  Article  Google Scholar 

  101. 101.

    Lee N, Chan PKS, Ip M, Wong E, Ho J, Ho C, et al. Anti-SARS-CoV IgG response in relation to disease severity of severe acute respiratory syndrome. J Clin Virol. 2006;35(2):179–84.

    CAS  PubMed  Article  Google Scholar 

  102. 102.

    Lei J, Li J, Li X, Qi X. CT imaging of the 2019 novel coronavirus (2019-nCoV) pneumonia. Radiology. 2020;200236.

  103. 103.

    Leung WK, To KF, Chan PK, Chan HL, Wu AK, Lee N, et al. Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection. Gastroenterology. 2003;125:1011–7.

    Article  PubMed  PubMed Central  Google Scholar 

  104. 104.

    Li BQ, Fu T, Dongyan Y, Mikovits JA, Ruscetti FW, Wang JM. Flavonoid baicalin inhibits HIV-1 infection at the level of viral entry. Biochem Biophys Res Commun. 2000;276(2000):534–8.

    CAS  Article  PubMed  Google Scholar 

  105. 105.

    Li G, Chen X, Xu A. Profile of specific antibodies to the SARS-associated coronavirus. N Engl J Med. 2003;349:508–9.

    Article  PubMed  Google Scholar 

  106. 106.

    Li Q, Guan X, Wu P, Zhou L, Tong Y, Ren R, et al. Early transmission dynamics in Wuhan China of novel coronavirus-infected pneumonia. N Engl J Med. 2020c.

  107. 107.

    Li W, Hulswit RJ, Widjaja I, Raj VS, McBride R, Peng W, et al. Identification of sialic acid binding function for the Middle East respiratory syndrome coronavirus spike glycoprotein. Proc Natl Acad Sci U S A. 2017;114:e8508–17.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  108. 108.

    Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal. 2020b;10(2):102–8.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  109. 109.

    Li X, Giorgi EE, Marichann MH, Foley B, Xiao C, Kong XP, et al. Emergence of SARS-CoV-2 through recombination and strong purifying selection. bioRxiv. 2020a.

  110. 110.

    Lim K, Liu D. The missing link in coronavirus assembly: retention of the avian coronavirus infectious bronchitis virus envelope protein in the preGolgi compartments and physical interaction between the envelope and membrane proteins. J Biol Chem. 2001;276(20):17515–23.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  111. 111.

    Lin CW, Tsai FJ, Tsai CH, Lai CC, Wan L, Ho TY. Anti-SARS coronavirus 3C-like protease effects of Isatis indigotica root and plant-derived phenolic compounds. Antivir Res. 2005;68(2005):36–42.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  112. 112.

    Lin SC, Ho CT, Chuo WH, Li S, Wang TT, Lin CC. Effective inhibition of MERS-CoV infection by resveratrol. BMC Infect Dis. 2017;17(2017):144.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  113. 113.

    Locker JK, Opstelten DJE, Ericsson M, Horzinek MC, Rottier PJ. Oligomerization of a trans-Golgi/trans-Golgi network retained protein occurs in the Golgi complex and may be part of its retention. J Biol Chem. 1995;270(15):8815–21.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  114. 114.

    Lotteau V, Teyton L, Peleraux A, Nilsson T, Karlsson L, Schmid SL, et al. Intracellular transport of class II MHC molecules directed by invariant chain. Nature. 1990;348:600–5.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  115. 115.

    Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565–74.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  116. 116.

    Madrid PB, Panchal RG, Warren TK, Shurtleff AC, Endsley AN, Green CE, et al. Evaluation of ebola virus inhibitors for drug repurposing. Infect Dis Ther. 2015;1(7):317–26.

    CAS  Google Scholar 

  117. 117.

    Matsuyama S, Ujike M, Morikawa S, Tashiro M, Taguchi F. Protease-mediated enhancement of severe acute respiratory syndrome coronavirus infection. Proc Natl Acad Sci U S A. 2005;102:12543–7.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  118. 118.

    McBride R, van Zyl M, Fielding BC. The coronavirus nucleocapsid is a multifunctional protein. Viruses. 2014;6(8):2991–3018.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  119. 119.

    Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  120. 120.

    Miller DK, Lenard J. Antihistaminics local anesthetics and other amines as antiviral agents. Proc Natl Acad Sci U S A. 1981;78:3605–9.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  121. 121.

    Millet JK, Whittaker GR. Host cell entry of Middle East respiratory syndrome coronavirus after two-step furin-mediated activation of the spike protein. Proc Natl Acad Sci U S A. 2014;111:15214–9.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  122. 122.

    Mukherjee P, Shah F, Desai P, Avery M. Inhibitors of SARS-3CLpro: virtual screening biological evaluation and molecular dynamics simulation studies. J Chem Inf Model. 2011;51(6):1376–92.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  123. 123.

    Narayanan K, Kim KH, Makino S. Characterization of N protein self-association in coronavirus ribonucleoprotein complexes. Virus Res. 2003;98(2):131–40.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  124. 124.

    Narayanan K, Maeda A, Maeda J, Makino S. Characterization of the coronavirus M protein and Nucleocapsid interaction in infected cells. J Virol. 2000;74(17):8127–34.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  125. 125.

    Nguyen TT, Woo HJ, Kang HK, Nguyen VD, Kim YM, Kim DW, et al. Flavonoid-mediated inhibition of SARS coronavirus 3C-like protease expressed in Pichia pastoris. Biotechnol Lett. 2012;34(2012):831–8.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  126. 126.

    Nieto-Torres JL, DeDiego ML, Álvarez E, Jiménez-Guardeño JM, Regla-Nava JA, Llorente M, et al. Subcellular location and topology of severe acute respiratory syndrome coronavirus envelope protein. Virology. 2011;415(2):69–82.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  127. 127.

    NIH (2019) The National Institutes of Health: Coronavirus Disease 2019 (COVID-19) treatment guidelines (Updated on: May 12, 2020) (Accessed on 29.08.2020).

  128. 128.

    Park JY, Kim JH, Kim YM, Jeong HJ, Kim DW, Park KH, et al. Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases. Bioorg Med Chem. 2012;20(19):5928–35.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  129. 129.

    Park JY, Ko JA, Kim DW, Kim YM, Kwon HJ, Jeong HJ, et al. Chalcones isolated from Angelica keiskei inhibit cysteine proteases of SARS-CoV. J Enzyme Inhib Med Chem. 2016;31(1):23–30.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  130. 130.

    Park WY, Goodman RB, Steinberg KP, Ruzinski JT, Radella F, Park DR, et al. Cytokine balance in the lungs of patients with acute respiratory distress syndrome. Am J Respir Crit Care Med. 2001;164:1896–903.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  131. 131.

    Paules CI, Marston HD, Fauci AS. Coronavirus infections—more than just the common cold. Jama. 2020;323(8):707–8.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  132. 132.

    Pawagi AB, Wang J, Silverman M, Reithmeier RA, Deber CM. Transmembrane aromatic amino acid distribution in P-glycoprotein: a functional role in broad substrate specificity. J Mol Biol. 1994;235(2):554–64.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  133. 133.

    Pawar AY. Combating devastating COVID −19 by drug repurposing. Int J Antimicrob Agents. 2020;105984.

  134. 134.

    Pedersen SF, Ho Y. SARS-CoV-2: a storm is raging. J Clin Invest. 2020;130(5):2202–5.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  135. 135.

    Perlman S. Another decade another coronavirus. N Engl J Med. 2020;382:760–2.

    PubMed  PubMed Central  Article  Google Scholar 

  136. 136.

    Perlman S, Netland J. Coronaviruses post-SARS: update on replication and pathogenesis. Nat Rev Microbiol. 2009;7:439–50.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  137. 137.

    Prabakaran P, Xiao X, Dimitrov DS. A model of the ACE2 structure and function as a SARS- CoV receptor. Biochem Biophys Res Commun. 2004;314(1):235–41.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  138. 138.

    Radbel J, Narayanan N, Bhatt PJ. Use of tocilizumab for COVID-19 infection-induced cytokine release syndrome: a cautionary case report. Chest. 2020.

  139. 139.

    Rainsford KD, Parke Ann L, Clifford-Rashotte M, Kean WF. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus rheumatoid arthritis and related diseases. Inflammopharmacology. 2015;23:231–69.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  140. 140.

    Raj S, Chandel V, Rathi B, Kumar D (2020a) Understanding the molecular mechanism (s) of SARS-CoV2 infection and propagation in human to discover potential preventive and therapeutic approach. Preprints. Doi:

  141. 141.

    Raj S, Chandel V, Rathi B, Kumar D. Understanding the molecular mechanism (s) of SARS-CoV2 infection and propagation in human to discover potential preventive and therapeutic approach; 2020b.

    Google Scholar 

  142. 142.

    Rakhmetullina A, Ivashchenko A, Akimniyazova A, Aisina D, Pyrkova A. The miRNA complexes against coronaviruses SARS-CoV-2, SARS-CoV, and MERS-CoV. Research Square. 2020.

  143. 143.

    Randolph VB, Winkler G, Stollar V. Acidotropic amines inhibit proteolytic processing of flavivirus prM protein. Virology. 1990;174:450–8.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  144. 144.

    Rathi S, Ish P, Kalantri A, Kalantri S. Hydroxycloroquine prohylaxis for COVID-19 contacts in India. The Lancet Infec Dis. 2020;20(1):1118-9.

  145. 145.

    Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395(10223):e30.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  146. 146.

    Rolain JM, Colson P, Raoult D. Recycling of chloroquine and its hydroxyl analogue to face bacterial fungal and viral infections in the 21st century. Int J Antimicrob Agents. 2007;30:297–308.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  147. 147.

    Ros C, Burckhardt CJ, Kempf C. Cytoplasmic trafficking of minute virus of mice: low-pH requirement routing to late endosomes and proteasome interaction. J Virol. 2002;76:12634–45.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  148. 148.

    Rosa SGV, Santos NC. Clinical trial on drug repositioning for COVID-19 treatment. Rev Pana De Salud Pub. 2020;44:e40.

    Article  Google Scholar 

  149. 149.

    Ruch TR, Machamer CE. The hydrophobic domain of infectious bronchitis virus E protein alters the host secretory pathway and is important for release of infectious virus. J Virol. 2011;85(2):675–85.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  150. 150.

    Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395:473–5.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  151. 151.

    Ryu YB, Jeong HJ, Kim JH, Kim YM, Park JY, Kim D, et al. Biflavonoids from Torreya nucifera displaying SARS-CoV-3CL (pro) inhibition. Bioorg Med Chem. 2010b;18(2010):7940–7.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  152. 152.

    Ryu YB, Park SJ, Kim YM, Lee JY, Seo WD, Chang JS, et al. SARS-CoV 3CLpro inhibitory effects of quinone-methide triterpenes from Tripterygium regelii. Bioorg Med Chem Lett. 2010a;20(6):1873–6.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  153. 153.

    Salazar-Bookaman MM, Wainer I, Patil PN. Relevance of drug-melanin interactions to ocular pharmacology and toxicology. J Ocul Pharmacol. 1994;10:217–39.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  154. 154.

    Salomon R, Hoffmann E, Webster RG. Inhibition of the cytokine response does not protect against lethal H5N1 influenza infection. Proc Natl Acad Sci U S A. 2007;104:12479–81.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  155. 155.

    Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;323(18):1824–36.

    CAS  PubMed  PubMed Central  Google Scholar 

  156. 156.

    Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today's diseases. Lancet Infect Dis. 2003;3(11):722–7.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  157. 157.

    Savarino A, Di Trani L, Donatelli I, Cauda R, Cassone A. New insights into the antiviral effects of chloroquine. Lancet Infect Dis. 2006;6:67–9.

    Article  PubMed  PubMed Central  Google Scholar 

  158. 158.

    Schelle B, Karl N, Ludewig B, Siddell SG. Thiel V. Selective replication of coronavirus genomes that express nucleocapsid protein. J Virol. 2005;79(11):6620–30.

  159. 159.

    Schwarz S, Sauter D, Wang K, Zhang R, Sun B, Karioti A, et al. Kaempferol derivatives as antiviral drugs against the 3a channel protein of coronavirus. Planta Med. 2014;80(2014):177–82.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  160. 160.

    Schwarz S, Wang K, Yu W, Sun B, Schwarz W. Emodin inhibits current through SARS-associated coronavirus 3a protein. Antivir Res. 2011;90(2011):64–9.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  161. 161.

    Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017;9(2017):eaal3653.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  162. 162.

    Sheahan TP, Sims AC, Leist S, Schäfer A, Won J, Brown AJ, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11(2020):222.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  163. 163.

    Shimabukuro-Vornhagen A, Gödel P, Subklewe M, et al. Cytokine release syndrome. J Immunother Cancer. 2018;6(1):56.

    Article  PubMed  PubMed Central  Google Scholar 

  164. 164.

    Shimizu Y, Yamamoto S, Homma M, Ishida N. Effect of chloroquine on the growth of animal viruses. Arch Gesamte Virusforsch. 1972;36:93–104.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  165. 165.

    Simmons G, Reeves JD, Rennekamp AJ, et al. Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. Proc Natl Acad Sci U S A. 2004;101:4240–5.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  166. 166.

    Singh AK, Singh A, Singh S, Misra A. Remdesivir in COVID-19: a critical review of pharmacology, preclinical and clinical studies. Diab Metabol Synd Clin Res Rev. 2020;14:641–8.

    Google Scholar 

  167. 167.

    Siu Y, Teoh K, Lo J, Chan C, Kien F, Escriou N, et al. The M E and N structural proteins of the severe acute respiratory syndrome coronavirus are required for efficient assembly trafficking and release of virus-like particles. J Virol. 2008;82(22):11318–30.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  168. 168.

    Song YH, Kim DW, Curtis-Long MJ, Yuk HJ, Wang Y, Zhuang N, et al. Papain-like protease (PLpro) inhibitory effects of cinnamic amides from Tribulus terrestris fruits. Biol Pharm Bull. 2014;37(6):1021–8.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  169. 169.

    Song Z, Xu Y, Bao L, Zhang L, Yu P, Qu Y, et al. From SARS to MERS thrusting coronaviruses into the spotlight. Viruses. 2019;11(1):59.

    CAS  Article  PubMed Central  Google Scholar 

  170. 170.

    Su B, Wang Y, Zhou R, Jiang T, Zhang H, Li Z, et al. Efficacy and tolerability of lopinavir/ritonavir- and efavirenz-based initial antiretroviral therapy in HIV-1-infected patients in a tertiary care hospital in Beijing China. Front Pharmacol. 2019;10:1472.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  171. 171.

    Su H, Yao S, Zhao W, Li M, Liu J, Shang W, et al. Discovery of baicalin andbaicalein as novel, natural product inhibitors of SARS-CoV-2 3CL protease in vitro. BioRxiv. 2020.

  172. 172.

    Su S, Wong G, Shi W, et al. Epidemiology genetic recombination and pathogenesis of coronaviruses. Trends Microbiol. 2016;24:490–502.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  173. 173.

    Sun P, Lu X, Xu C, Sun W, Pan B. Understanding of COVID-19 based on current evidence. J Med Virol. 2020;25722.

  174. 174.

    Swank K, McCartan K, Kapoor R, Gada N, Diak I-L (2020) Pharmacovigilance memorandum. By: Department of Health and Human Services, public health service, Food and Drug Administration, Center for Drug Evaluation and Research, Office of Surveillance and Epidemiology (updated July 1, 2020) (Accessed on 30.08.2020).

  175. 175.

    Tang J, Zhang N, Tao X, Zhao G, Guo Y, Tseng CTK, et al. Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus. Human Vacc Immunother. 2015;11(5):1244–50.

    Article  Google Scholar 

  176. 176.

    Tang X, Wu C, Li X, Song Y, Yao X, Wu X, et al. On the origin and continuing evolution of SARS-CoV-2. Natl Sci Rev. 2020;7(6):1012–23.

    Article  Google Scholar 

  177. 177.

    Tett SE, Cutler DJ, Day RO. Antimalarials in rheumatic diseases. Baillieres Clin Rheumatol. 1990;4:467–89.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  178. 178.

    Tett SE, Cutler DJ, Day RO, Brown KF. Bioavailability of hydroxychloroquine tablets in healthy volunteers. Br J Clin Pharmacol. 1989;27:771–9.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  179. 179.

    Thorlund K, Dron L, Park J, Hsu G, Forrest JI, Mills E. A real-time dashboard of clinical trials for COVID-19. Lancet Digi Heal. 2020;2(2020):e286–7.

    Article  Google Scholar 

  180. 180.

    Tooze J, Tooze S, Warren G. Replication of coronavirus MHV-A59 in sac-cells: determination of the first site of budding of progeny virions. Eur J Cell Biol. 1984;33(2):281–93.

    CAS  PubMed  PubMed Central  Google Scholar 

  181. 181.

    Tortorici MA, Walls AC, Lang Y, Wang C, Li Z, Koerhuis D, et al. Structural basis for human coronavirus attachment to sialic acid receptors. Nat Struct Mol Biol. 2019;26:481–9.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  182. 182.

    Tyrrell DAJ, Bynoe ML. Cultivation of a novel type of common-cold virus in organ cultures. Brit Med J. 1965;1:1467–70.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  183. 183.

    Uzunova K, Filipova E, Pavlova V, Vekov T. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2. Biomed Pharmacother. 2020.

  184. 184.

    van den Borne BE, Dijkmans BA, de Rooij HH, le Cessie S, Verweij CL. Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha interleukin-6 and interferongamma production by peripheral blood mononuclear cells. J Rheumatol. 1997;24:55–60.

    PubMed  PubMed Central  Google Scholar 

  185. 185.

    Van Ierssel S, Dauby N, Bottieau E. et al. (2020) Interim clinical guidance for adults with suspected or confirmed COVID-19 in Belgium, Version 8 (added on 4/7/2020) (accessed on 29.08.2020).

  186. 186.

    Venkatagopalan P, Daskalova SM, Lopez LA, Dolezal KA, Hogue BG. Coronavirus envelope (E) protein remains at the site of assembly. Virology. 2015;478:75–85.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  187. 187.

    Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. J Virol. 2005;2:69.

    CAS  Article  Google Scholar 

  188. 188.

    Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure function and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181(2):281–92.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  189. 189.

    Wan S, Xiang Y, Fang W, Zheng Y, Li B, Hu Y, et al. Clinical features and treatment of COVID-19 patients in Northeast Chongqing. J Med Virol. 2020;25783.

  190. 190.

    Wang H, Jiang C. Influenza a virus H5N1 entry into host cells is through clathrin-dependent endocytosis. Sci ChinaC Life Sci. 2009;52:464–9.

    CAS  Article  Google Scholar 

  191. 191.

    Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020c;30:269–71.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  192. 192.

    Wang SF, Chen KH, Chen M, et al. Human-leukocyte antigen class I Cw 1502 and class II DR 0301 genotypes are associated with resistance to severe acute respiratory syndrome (SARS) infection. Viral Immunol. 2011;24:421–6.

    CAS  Article  PubMed  Google Scholar 

  193. 193.

    Wang Y, Wang Y, Chen Y, Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. J Med Virol. 2020a;92(6):568–76.

    CAS  Article  Google Scholar 

  194. 194.

    Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020d;395(10236):1569–78.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  195. 195.

    Wang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. BioSci Trend Adv Pub. 2020b;01030.

  196. 196.

    Wen CC, Kuo YH, Jan JT, Liang PH, Wang SY, Liu HG, et al. Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus. J Med Chem. 2007;50(17):4087–95.

    CAS  PubMed  Article  Google Scholar 

  197. 197.

    Wetsteyn JC, De Vries PJ, Oosterhuis B, Van Boxtel CJ. The pharmacokinetics of three multiple dose regimens of chloroquine: implications for malaria chemoprophylaxis. Br J Clin Pharmacol. 1995;39:696–9.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  198. 198.

    WHO. Weekly epidemiological upadate: coronavirus disease 2019 (COVID-19); 2020a. 24 August 2020. (Accessed on 28.08.2020).

    Google Scholar 

  199. 199.

    WHO. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected; 2020b. (Accessed on 28.01.2020).

    Google Scholar 

  200. 200.

    WHO (2020c) Advice on the use of point-of-care immunodiagnostic tests for COVID-19: Scientific Brief 8 April 2020 (No. WHO/2019-CoV/Sci_Brief/POC_immunodiagnostics/2020.1). World Health Organization. (Accessed on 09.07.2020).

  201. 201.

    Widge AT, Rouphael NG, Jackson LA, Anderson EJ, Roberts PC, Makhene M, et al. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. N Engl J Med. 2020.

  202. 202.

    Wise J. COVID-19: Remdesivir is recommended for authorisation by European medicines agency. BMJ. 2020;369:m2610.

    Article  PubMed  PubMed Central  Google Scholar 

  203. 203.

    Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion confirmation. Science. 2020;367(6483):1260–3.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  204. 204.

    Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, et al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe. 2020a;27(3):325–8.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  205. 205.

    Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020b.

  206. 206.

    Wu SF, Chang CB, Hsu JM, Lu MC, Lai NS, Li C, et al. Hydroxychloroquine inhibits CD154 expression in CD4(+) T lymphocytes of systemic lupus erythematosus through NFAT but not STAT5 signaling. Arthritis Res Ther. 2017;19:183.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  207. 207.

    Wu W, Li R, Li X, He J, Jiang S, Liu S, et al. Quercetin as an antiviral agent inhibits influenza a virus (IAV) entry. Viruses. 2015;8(1):6.

    CAS  Article  PubMed Central  Google Scholar 

  208. 208.

    Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with Tocilizumab. Proc Natl Acad Sci U S A. 2020b;117(20):10970–5.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  209. 209.

    Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020a.

  210. 210.

    Yam LY, Lau AC, Lai FY, Shung E, Chan J, Wong V. Corticosteroid treatment of severe acute respiratory syndrome in Hong Kong. J Inf Secur. 2007;54:28–39.

    Google Scholar 

  211. 211.

    Yamada Y, Hidefumi K, Shion H, Oshikata M, Haramaki Y. Distribution of chloroquine in ocular tissue of pigmented rat using matrix-assisted laser desorption/ionization imaging quadrupole time-of-flight tandem mass spectrometry. Rapid Commun Mass Spectrom. 2011;25:1600–8.

    CAS  PubMed  Article  Google Scholar 

  212. 212.

    Yan H, Ma L, Wang H, Wu S, Huang H, Gu Z, et al. Luteolin decreases the yield of influenza a virus in vitro by interfering with the coat protein I complex ex-pression. J Nat Med. 2019;73(2019):487–49.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  213. 213.

    Yang M, Chen F, Zhu D, Li J, Zhu J, Zeng W, et al. Clinical efficacy of Matrine and sodium chloride injection in treatment of 40 cases of COVID-19. China J Chinese Mater Med. 2020:1–12.

  214. 214.

    Yang ZY, Huang Y, Ganesh L, Leung K, Kong WP, Schwartz O. pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. J Virol. 2004;78:5642–50.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  215. 215.

    Yin Y, Wunderink RG. MERS SARS and other coronaviruses as causes of pneumonia. Respirology. 2018;23(2):130–7.

    PubMed  Article  Google Scholar 

  216. 216.

    Yu B, Dai CQ, Jiang ZY, Li EQ, Chen C, Wu XL, et al. Andrographolide as ananti-H1N1 drug and the mechanism related to retinoic acid-inducible gene-I-likereceptors signaling pathway. Chin J Integr Med. 2014;20(2014):540–5.

    CAS  Article  PubMed  Google Scholar 

  217. 217.

    Yu Y, Zhang Y, Wang S, Liu W, Hao C, Wang W. Inhibition effects of patchoulialcohol against influenza a virus through targeting cellular PI3K/Akt and ERK/MAPK signalling pathways. Virol J. 2019;16:163.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  218. 218.

    Yuan Q, Liao Y, Torres J, Tam J, Liu D. Biochemical evidence for the presence of mixed membrane topologies of the severe acute respiratory syndrome coronavirus envelope protein expressed in mammalian cells. FEBS Lett. 2006;580(13):3192–200.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  219. 219.

    Yuan Y, Duanfang C, Yanfang Z, Jun M, Jianxun Q, Qihui W, et al. Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding dosumains. Nature Comm. 2017;8:15092.

    CAS  Article  Google Scholar 

  220. 220.

    Zhang C, Wu Z, Li J, Zhao H, Wang G. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents. 2020c;55(5):105954.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  221. 221.

    Zhang D, Wu K, Zhang X, Deng S, Peng B. In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus. J Integr Med doi. 2020a.

  222. 222.

    Zhang Q, Wang Y, Qi C, Shen L, Li J. Clinical trial analysis of 2019-nCoV therapy registered in China. J Med Virol. 2020b;92(6):540–5.

    CAS  PubMed  Article  Google Scholar 

  223. 223.

    Zhang T, Han Z, Xu Q, Wang Q, Gao M, Wu W, et al. Serotype shift of a 793/B genotype infectious bronchitis coronavirus by natural recombination. Infect Genet Evol. 2015;32:377–87.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  224. 224.

    Zhang W, Zhao Y, Fengchun Z, Qian W, Taisheng L, Zhengyin L, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the experience of clinical immunologists from China. Clin Immunol. 2020d;108393.

  225. 225.

    Zhang YZ, Holmes EC. A genomic perspective on the origin and emergence of SARS-CoV-2. Cell. 2020;181(2):223–7.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  226. 226.

    Zhou D, Dai SM, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother. 2020;75(7):1667–70.

    CAS  Article  PubMed  Google Scholar 

  227. 227.

    Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China 2019. N Engl J Med. 2020;382(8):727–33.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  228. 228.

    Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronaviruses – drugdiscovery and therapeutic options. Nat Rev Drug Discov. 2016;15(5):327–47.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

Download references


Authors are thankful to Dr. Gaurav Deep Singh (Secretary) Sardar Bhagwan Singh University, Dehradun, India for providing facilities in the completion of the article.


This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author information




JC, SD, KT, PK, MKS, AKC, GV, NB written the manuscript, SD, SKK and VS designed and framed the manuscript and overall directed to bring in the shape. Moreover, all the authors had gone through the manuscript and revised it technically before submission. The authors read and approved the final manuscript.

Corresponding authors

Correspondence to Shrivardhan Dheeman or Vipin Sharma or Santosh Kumar Karn.

Ethics declarations

Ethics approval and consent to participate

The ethical approval or individual consent was not applicable.

Consent for publication

All authors has consent for the publication.

Competing interests

There arenot any competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Choudhary, J., Dheeman, S., Sharma, V. et al. Insights of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) pandemic: a current review. Biol Proced Online 23, 5 (2021).

Download citation


  • COVID-19
  • Coronavirus
  • ACE-2 receptor
  • Drug repurposing